



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Adapting and validating an instrument to assess informed consent comprehension among youth and parents in rural western Kenya

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021613
Article Type:	Research
Date Submitted by the Author:	12-Jan-2018
Complete List of Authors:	Afolabi, Muhammed; London School of Hygiene and Tropical Medicine, Clinical Research Rennie, Stuart; UNC School of Medicine Charlotte Campus Halifors, Denise; Pacific Institute for Research and Evaluation (PIRE) Kline, Tracy; RTI International Zeitz, Susannah ; University of North Carolina, Department of Health Behavior; Pacific Institute for Research and Evaluation (PIRE) Odongo, Frederick; Center for Global Health Research, Kenya Medical Research Institute (KEMRI) Amek, Nyaguara ; Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Luseno, Winnie; Pacific Institute for Research and Evaluation (PIRE)
Keywords:	informed consent, understanding, tool, validation, Africa

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Adapting and validating an instrument to assess informed consent comprehension among youth and parents in rural western Kenya**

Muhammed O. Afolabi<sup>1</sup>, Stuart Rennie<sup>2</sup>, Denise Dion Hallfors<sup>3</sup>, Tracy Kline<sup>4</sup>, Susannah Zeitz<sup>3,5</sup>, Frederick S. Odongo<sup>6</sup>, Nyaguara O. Amek<sup>6</sup>, Winnie K. Luseno<sup>3</sup>

- <sup>1</sup>Department of Clinical Research, London School of Hygiene & Tropical Medicine, UK;
- <sup>2</sup>Department of Social Medicine, UNC School of Medicine, USA;
- <sup>3</sup>Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, North Carolina, USA;
- <sup>4</sup>RTI International, Research Triangle Park, North Carolina, USA;
- <sup>5</sup>Department of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, USA.
- <sup>6</sup>Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya

**Corresponding author:** Dr Muhammed Afolabi, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, United Kingdom. E-mail: [Muhammed.Afolabi@lsthm.ac.uk](mailto:Muhammed.Afolabi@lsthm.ac.uk); [afolabimo@gmail.com](mailto:afolabimo@gmail.com)

**Funding Statement:** The research reported in this publication was sponsored by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH102125 (Winfred [Winnie] K. Luseno, Principal Investigator). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Statement of data sharing:** Exclusive use of the data will be maintained by the Principal Investigator (PI), Dr. W. K. Luseno, until the publication of major outputs. Thereafter, following approvals by the institutional review boards of PIRE and KEMRI, de-identified data will made available to the scientific community through requests made to the PI at [wluseno@pire.org](mailto:wluseno@pire.org)

**Competing Interest:** Authors declared no conflict of interest

**Authors' contributions:** Design of study: WL, DH, and MOA; drafting and reviewing questionnaires: DH, WL, MOA, and SR; acquiring data: WL, FSO, and NOA; analysing data: TK, SZ, DH, WL, and MOA; writing the manuscript: MOA, SR, DH, WL, TK, SZ, and NOA.

**Acknowledgements:** The authors thank all the study participants and field staff who contributed to this Research. This work was done in collaboration with Kenya Medical Research Institute (KEMRI), Center for Global Health Research, Kisumu.

## Abstract

**Objective:** To adapt and validate a questionnaire originally developed in a research setting for assessment of comprehension of consent information in a different cultural and linguistic research setting.

**Design:** The adaptation process involved development and customization of a questionnaire for each of the three study groups, modeled closely on the previously validated questionnaire. The three adapted draft questionnaires were further reviewed by two bioethicists and the developer of the original questionnaire for face and content validity. The revised questionnaire was subsequently programmed into an audio-computerized format, with translations and back-translations in three widely spoken languages by the study participants: Luo, Swahili, and English.

**Setting:** The questionnaire was validated amongst adolescents, their parents, and young adults living in Siaya County, a rural region of western Kenya.

**Participants:** 25-item adapted questionnaires consisting of close-ended, multiple-choice, and open-ended questions were administered to 235 participants consisting of 107 adolescents, 92 parents and 36 young adults. Test-retest was conducted 2-4 weeks after first questionnaire administration amongst 74 adolescents, young adults, and parents.

**Outcome measure:** Primary outcome measures included ceiling/floor analysis to identify questions with extremes in responses and item-level correlation to determine the test-retest relationships. Given the data format, tetrachoric correlations were conducted for dichotomous items and polychoric correlations for ordinal items.

**Results:** Ceiling/floor analysis showed eight question items for which >80% of one or more groups responded correctly, while for nine questions, including all seven open-ended questions, <20%

58 responded correctly. Majority of the question items had moderate to strong test-retest correlation  
59 estimates indicating temporal stability.

60 **Conclusions:** Our study demonstrates that cross-cultural adaptation and validation of an informed  
61 consent comprehension questionnaire is feasible. However, further research is needed to develop a  
62 tool which can estimate a quantifiable threshold of comprehension thereby serving as an objective  
63 indicator of the need for interventions to improve comprehension.

64 **Keywords:** informed consent, understanding, tool, validation, Africa

**Strengths and limitations of this study:**

- Our study demonstrates feasibility of cross-cultural adaptability and validation of an informed consent comprehension tool developed in two differently diverse linguistic settings
- Despite limitations of small sample size and disparate modes of parental consenting; test- retest correlations showed moderate to strong temporal stability for majority of the question items.
- Our study results reinforce calls to develop innovative and culturally responsive ways to present research-related information, beyond the standard method of reading consent forms.
- Our tool does not suggest a quantifiable threshold of comprehension below which the consent of participants is invalidated.

## 74 Introduction

75 Informed consent is a key ethical requirement in clinical research. Universally agreed guidelines  
76 highlight four elements of informed consent which normally must be satisfied before proceeding  
77 with the conduct of scientific research involving human participants. These elements include  
78 decisional competence, disclosure of study information, comprehension and voluntariness (1-4). Of  
79 these elements, comprehension of consent information by a prospective research participant is  
80 critical to the quality of a consent procedure as it determines how the participant is empowered to  
81 use the information to arrive at an informed decision on whether or not to participate in the study  
82 (5). The informed consent process is typically built on the notion that individuals considering  
83 participation have demonstrated satisfactory understanding of the consent information (6).  
84 However, empirical evidence has shown that research participants frequently do not understand  
85 significant aspects of the studies they join, such as the difference between participating in clinical  
86 research and receiving medical care, i.e. 'therapeutic misconception'(7). They also demonstrate poor  
87 understanding of the concepts of randomisation, research risk and benefits and right of withdrawal  
88 (8-10).  
89 Very few studies have assessed research participant comprehension of consent information in  
90 African populations. In a systematic review with meta-analysis of 21 studies conducted across  
91 several African countries, comprehension of key concepts of informed consent was poor, with less  
92 than half of the study participants demonstrating understanding of research concepts such as  
93 randomisation and placebo, and with only 30% being aware of participating in clinical research (11).  
94 Conversely, another systematic review focusing on 103 studies conducted mainly in middle and high-  
95 income countries over a period of 30 years, showed that more than 70% of participants had good  
96 understanding of different domains of informed consent including nature of the study, voluntary  
97 participation, and rights of withdrawal while appreciable proportions of the participants  
98 demonstrated no therapeutic misconceptions and were aware of the study risks and benefits (12).

99 This contrast between the ideals of informed consent and the reality of informed consent in practice  
100 is especially marked in settings with high illiteracy rates or mistrust of research institutions, or where  
101 signatures are rarely employed for transacting business. Over-emphasis on written documents can  
102 further aggravate these challenges to effective communication, particularly when participants are  
103 asked to understand complex information contained in lengthy informed consent documents written  
104 in international languages with unfamiliar terms and concepts (13).

105  
106 To ensure participants make meaningful decisions that protect their rights and freedom of choice,  
107 researchers in socially and economically disadvantaged communities have been advised to make  
108 efforts to help prospective participants attain satisfactory understanding of informed consent (2). To  
109 help achieve this, a context-sensitive tool is required to assess participant comprehension of  
110 components of consent information delivered during an informed consent discussion. The tool  
111 would help to indicate areas of miscomprehension and could further serve as a platform to develop  
112 appropriate interventions to improve the identified areas which participants do not understand.

113 The development and psychometric evaluation of a Digitised Informed Consent Comprehension  
114 Questionnaire (DICCQ) has been reported elsewhere (14). Briefly, the tool was developed following  
115 meticulous identification of domains of informed consent which are poorly understood by research  
116 participants in low literacy communities in Africa. Owing to the peculiar challenge of inability to read  
117 and comprehend informed consent written in international languages, the questionnaire was  
118 developed into an audio computerised tool in the participants' local languages. The tool was  
119 administered to assess the understanding of individuals participating in studies taking place in rural  
120 and urban settings of The Gambia, a small West African country characterised with an adult literacy  
121 rate of less than 50% (15). Although the tool was reported to be a reliable and valid measure of  
122 informed consent comprehension (14), concerns existed regarding whether the tool would retain its  
123 acceptable properties if adapted for use in alternate African settings with diverse cultural and  
124 linguistic variations.

Given that empirical assessment of consent comprehension is in its infancy and that instrument development and validation are a lengthy but critical process, we focus on the cultural adaptation and evaluation of the DICCQ amongst a diverse population of adolescents, young adults and parents in a rural setting in western Kenya, East Africa. The initial validation of the DICCQ has been previously published (14), and is the basis for the instrument which was modified for relevance and tested among the three age-groups in Kenya. This work is part of a study on the effects of HIV test disclosure on adolescent behavior and well-being to inform guidelines for the ethical conduct of adolescent HIV-related research in sub-Saharan Africa. Along with HIV testing, we are investigating comprehension during the informed consent process among parents and youth. The current paper focuses on the first phase of activities to assess informed consent comprehension. The activities included the adaptation of the DICCQ instrument, which was developed for adults, for use among adolescents and their parents, as well as young adults; content validation, and a test-retest assessment of the adapted instrument.

### **The original DICCQ: constructs and validation**

As highlighted above, the question items on the DICCQ were generated from basic elements of informed consent obtained from literature on guidelines for contextual development of informed consent tools (13, 16-24), international ethical guidelines (3, 25) and operational guidelines from The Gambia's National Ethics Committee (26). Of these, 15 independent domains of informed consent that were not appropriately understood among study participants in low literacy settings were identified. These domains included voluntary participation, rights of withdrawal, study knowledge, study procedures, study purpose, blinding, confidentiality, compensation, randomization, autonomy, meaning of giving consent, benefits, risks/adverse effects, therapeutic misconception and placebo. DICCQ was face-validated by a carefully selected panel of researchers with expertise in research methodology and bioethics in the African context. The panel assessed the tool's readability, clarity of words used, consistency of style and likelihood of target participants being able to answer the



150 questions. This same expert panel also assessed content validity to establish whether the content of  
151 the questionnaire was appropriate and relevant to the context for which it was developed (27). The  
152 tool was revised based on the feedback from these experts. The revised questionnaire was further  
153 content-validated by randomly selected research assistants and three independent lay persons to  
154 assess clarity and appropriateness of the revised question items and their response options.

155 Given the lack of acceptable systems of writing in Gambian local languages, the question items were  
156 audio-recorded in three major local languages by experienced native speaking linguistic  
157 professionals who were also familiar with clinical research concepts. Audio back-translations were  
158 done for each language by three independent native speakers and corrections were made in areas  
159 where translated versions were not consistent with the English version. A final proof of the audio-  
160 recordings was conducted by three native speaking clinical researchers who independently  
161 confirmed that the translated versions retained the original meaning of the English version.

162 The revised questionnaire was developed into an audio computer-assisted self-interview (ACASI)  
163 format and referred to as the DICCQ(14). The tool was administered to 250 participants in two  
164 studies taking place concurrently in rural and urban Gambian settings. Half of these participants  
165 were recalled in one to two weeks after the first administration for a re-test. Previously published  
166 findings showed that the DICCQ had good psychometric properties with potential as a useful tool for  
167 measuring comprehension of informed consent amongst research participants in low literacy African  
168 settings (14).

169 For the present study, we adapted the DICCQ for three groups: minor adolescents (15-17 years),  
170 their parents, and young adults (18-19 years). Although some questions could be considered generic  
171 for research studies (such as voluntary participation, confidentiality, and rights of withdrawal),  
172 others are specific and required adaptation (such as purpose of the study, benefits, and risks). For  
173 minor adolescents and their parents, questions related to voluntary participation also required  
174 adaptation for comprehension of concepts related to adolescent assent and parental permission. In

175 this paper, we describe our validation methods and results, provide the resulting surveys, and  
176 discuss issues related to the assessment of comprehension of study information by participants in  
177 rural sub-Saharan settings. We refer to the adapted questionnaire as the Informed Consent  
178 Comprehension Assessment (ICCA).

## 179 **Methods**

### 180 *Validation Sample*

181 At the start of the parent study, we invited all consented participants from 10 randomly selected  
182 village clusters in one sub-county within Siaya County to respond to the ICCA. The first 235 to agree  
183 comprised the ICCA validation sample. These included minor adolescents (n=107), their parents  
184 (n=92), and young adults (n=36). Parents were invited if their adolescent child (or children) was  
185 selected for the ICCA study. More than half of the parents (N=49) who took the ICCA were not  
186 consented by staff but rather signed a consent form that their adolescent brought home to them.

### 187 *Adaptation and Validation Procedures*

188 We began our adaptation process by developing an ICCA questionnaire for each of the three groups,  
189 modeled closely on the DICCQ. We then customized two questions for minor adolescents about  
190 voluntary participation (i.e. need for parental permission for participation, and adolescent's rights to  
191 refuse). For parents, questions were adapted as needed to refer to their child as the main study  
192 participant. Finally, questions with study-specific content were developed, using content from IRB-  
193 approved consent forms. The three draft adapted questionnaires were then reviewed by two  
194 bioethicists and the developer of the original DICCQ for face and content validity, based on study  
195 protocols and the US federal regulations (4). Suggestions to clarify language and responses from this  
196 expert review were incorporated into the second draft.

197 The revised questionnaire was then programmed for ACASI format, with translations and back-  
198 translations in three languages (Luo, Swahili, and English). Next, we conducted pilot tests of the

199 questionnaires with local Kenyan parent and youth advisory group members (28) to determine  
200 whether consent form information and ICCA items were consistent/non-contradictory. After each of  
201 the three groups (minor adolescents, young adults, and parents) completed the appropriate version  
202 of the ICCA, we asked participants, individually and in separate focus groups, for their opinions  
203 about the consent form, ICCA questions, administration of the ICCA using ACASI format, and staff  
204 assistance (if requested) to type in responses to the open-ended questions. Based on feedback from  
205 participants, we revised the wording of one question's response categories, dropped one question,  
206 and revised the consent form to more clearly describe all aspects covered in the ICCA.

207 Subsequently, we administered the ICCA to our validation sample 2-4 weeks after consent and  
208 immediately prior to the baseline data collection. Adolescents who consented with the parent-child  
209 form took the Adolescent ICCA; those who consented with the young adult form took the Young  
210 Adult ICCA; and parents took the Parent ICCA. Of the sample, 74 were re-tested 1-2 weeks later for  
211 test-retest analyses. Participant selection for the re-test was sequential (every second person),  
212 stratified by study site. If one refused, staff continued with the sequence (i.e., skipping the next  
213 eligible and selecting the following).

#### 214 *Instrumentation*

215 Each ICCA survey consisted of a set of 25 yes/no, multiple-choice, and open-ended questions.  
216 Responses to the yes/no and multiple-choice questions were coded 0-1 for incorrect/correct  
217 answers, respectively. Responses to the open-ended questions were independently coded from  
218 completely incorrect to completely correct (0-4) by a panel of three researchers who discussed their  
219 scores and, if different, came to consensus on a single score per case. Responses were also  
220 dichotomized (0-1=incorrect; 2-4=correct) for ceiling/floor analysis. The three survey tools  
221 (Adolescent, Young Adult, and Parent) were generally similar. However, only seven questions and  
222 response options were identical across the three samples. Sixteen additional items were identical for  
223 adolescents and young adults. Two items were adolescent-specific, two were young adult-specific,

224 and 18 items were parent-specific. In addition to the questions on comprehension of informed  
225 consent, the ICCA also included socio-demographic items.

### 226 *Ethical considerations*

227 Ethical approval was obtained from the Institutional Review Boards of the Pacific Institute for  
228 Research and Evaluation (PIRE), USA, and Kenya Medical Research Institute (KEMRI). Written  
229 informed parent/guardian consent and youth assent was obtained for adolescents younger than 18  
230 years old; individuals who were 18 years or older or emancipated minors provided written informed  
231 consent. Participation was voluntary and private.

### 232 233 *Validation and Reliability Data Analysis*

234 All analyses were conducted using Stata 13.0 (College Station, USA). First, we conducted descriptive  
235 statistics to determine the magnitude of missing data in each of the ICCA items as well as questions  
236 with extremes in responding, i.e., to which > 80% in any one group responded correctly or  
237 incorrectly (ceiling/floor analyses). Because high comprehension is desirable for ethical consent, we  
238 were particularly interested in questions which fewer than 20% of the sample answered correctly,  
239 since this may indicate a problem in wording, format, or translation, as well as comprehension.

240 Second, we conducted test-retest analysis to assess temporal stability of the ICCA questions, i.e.,  
241 whether they were reliable in eliciting the same response at initial presentation (test) and at the  
242 second presentation one to two weeks later (re-test). Item level correlations were examined to  
243 determine the test-retest relationships. Due to data format, tetrachoric correlations were  
244 conducted for dichotomous items and polychoric correlations were conducted for ordinal items  
245 (open-ended scores) with the user-created polychoric package (29). We used the following  
246 benchmarks to interpret the correlation coefficients: below 0.5 was considered low, 0.5 to 0.69 was  
247 moderate, and 0.7 and higher was strong. We interpreted moderate and strong correlation  
248 coefficients as indicating acceptable temporal stability. Post-hoc analyses, specifically cross-

tabulations of participant responses at test and re-test, were conducted to further explore low correlations and to examine relationships in the data where correlation coefficients could not be obtained.

**Results**

Table 1 shows the demographics of the validation sample, including age, gender, religion and the relationship between the adolescent and the person who gave permission for the adolescent to join the study. As can be seen, about 71% of adults who gave permission for adolescent study participation identified as parents.

**Table 1: Demographic characteristics of study participants, Kenya, 2017**

Demographics	Adolescents	Young Adults	Parents
Age			
Median	16	18	42
Range	15-17	18-19	23-95
Interquartile Range	1	1	19
Gender			
Male	60 (56.1%)	18 (50%)	22 (23.9%)
Female	47 (43.9%)	18 (50%)	70 (76.1%)
Currently enrolled in school: N(%)	105 (98.1%)	26 (72.2%)	N/A
Highest level of education: N(%)			
Never gone to school	0 (0%)	0 (0%)	6 (6.5%)
Did not complete primary (< Std/Class 8)	72 (67.3%)	5 (13.9%)	37 (40.2%)
Completed primary (Std/Class 8)	10 (9.3%)	7 (19.4%)	24 (26.1%)
Did not complete secondary (< Form 4)	25 (23.4%)	24 (66.7%)	10 (10.9%)
Completed secondary (Form 4)	0 (0%)	0 (0%)	12 (13.0%)
College or University	0 (0%)	0 (0%)	3 (3.3%)
Attended vocational school: N(%)	0 (0%)	2 (5.6%)	12 (13.0%)
Religion: N(%)			
Roman Catholic	16 (15.0%)	4 (11.1%)	16 (17.4%)
Protestant/Other Christian	90 (84.1%)	31 (86.1%)	76 (82.6%)
Muslim	0 (0%)	1 (2.8%)	0 (0%)
No Religion	1 (0.9%)	0 (0%)	0 (0%)
Attending religious services once/week or more: N(%)	39 (36.4%)	20 (55.6%)	52 (56.5%)
Relationship with adolescent: N(%)			
Parent	N/A	N/A	65 (70.7%)
Other	N/A	N/A	27 (29.3%)
Staff present at consenting: N(%)	N/A	N/A	43 (46.7%)

Descriptive analyses showed that there were no questions with more than 5% missing data. The item with the largest percentage amount of missing responses (4%) was the open-ended study risk question (*Are there any bad things that could happen by taking part in this study? If yes, what are they?*). Ceiling/floor analysis showed eight questions for which >80% of one or more groups responded correctly, while for nine questions, <20% responded correctly (Table 2). All seven open-ended questions were among the latter category.

**Table 2. Ceiling Floor Results by Group, showing percent in each group that got item correct~**

Items that more than 80% of group got right (Ceiling)	Adolescents (age 15-17 years; N=107)	Young Adults (age 18-19 years; N=36)	Parents (N=92)
T-shirt for Participation	93.5	97.2	80.4*
Study Activities for Youth	91.6	91.7	
HIV Test Results Disclosure	94.4	94.4	90.2
Voluntary Withdrawal		94.4	85.9
Decisions for Study Participation	NA	88.9	
What Happens if you stop Study Participation		86.1	
Purpose of conducting study		88.9	
Voluntary Participation	NA	100	93.5
Items that more than 80% of group got wrong (Floor)	Adolescents (age 15-17 years; N=107)	Young Adults (age 18-19 years; N=36)	Parents (N=92)
Mode of Group Selection	19.8		17.4*
Study Benefits	16.8	16.7	19.6*
Research Purpose (open)**	1.1	13.3	1.1
Study Duration (open)	13.1		9.8
What is Next after HIV Test Results (open)	14.0		
Study HIV Test Vs Clinic HCT (open)	7.7	0	2.2
Study Risks (open)	9.3		13.0
Whom to Call (open)	10.5	19.4	19.6*
Study Eligibility (open)			7.7

~ Percent only shown if ceiling/floor cutoff met.

\* Parents who consented without staff present would not have met criterion for ceiling; parents who consented with staff would not meet criterion for floor.

271 **\*\***(open) denotes open-ended questions, (response range = 0-4). These were dichotomized for  
 272 floor/ceiling analysis: 0=0-1, 1=2-4.

273 As shown in Table 3, the great majority of items, when analyzed within groupings of the same  
 274 wording, had moderate to strong test-retest correlation estimates, despite small sample size,  
 275 suggesting temporal stability. These included all seven items with identical question and response  
 276 wording for the entire test-retest sample (n=74); 12 of the 16 items with identical question wording  
 277 and response options for young adults and adolescents (n=45); one of the two questions specific to  
 278 adolescents (n=33); and 10 of the 18 questions specific to parents (n=29). Seven items, however, had  
 279 low correlations, while eight could not be estimated because of small sample sizes and/or near  
 280 perfect correlation.

281 Three of the 16 items with identical question/response wording for young adults and adolescents  
 282 had low correlation coefficients ranging between 0.19 and 0.47. Of these, one was the open-ended  
 283 item, *"What will you be asked to do as a participant in the study after you receive your HIV test*  
 284 *results?"* In cross tabulation, 34 participants (77%) gave the same response at test and retest while,  
 285 six answered correctly at test and incorrectly at retest. For the item, *"What does it mean when you*  
 286 *sign the study consent form?"* 26 (58%) gave the same answer at test and retest, while three  
 287 answered correctly at test and incorrectly at retest. For the item, *"Which describes the main benefit*  
 288 *of taking part in the study?"* 34 participants (75%) gave the same answer at both test and retest,  
 289 while seven answered incorrectly at test and correctly at retest. Finally, a correlation coefficient  
 290 could not be obtained for the item *"Will you be told your HIV test results during the study?"* because  
 291 of a lack of variation at retest, with 41 (91%) and 45 (100%) answering correctly at test and retest,  
 292 respectively.

293  
 294  
 295  
 296  
 297



**Table 3. Correlational Results for Questions Common to All and Specific to Adolescents, Young Adults, and Parents (n=74)\***

Question	N	Tetrachoric/ Polychoric
<b>Common to All</b>		
Have you been given the name and phone number of the person to contact if you have any questions about the study?	74	0.86
Will you receive a T-shirt for taking part in the study?	74	0.6
How were participants selected into different groups in this study?	74	0.57
In your own words, can you tell me what the purpose of the research study is? (open)	73	-0.92
What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (open)	72	0.87
Are there any bad things that could happen by taking part in this study? If yes, what are they? (open)	70	0.9
If you had a question or concern about the study, who would you call? (open)	74	0.72
<b>Young Adults and Adolescents</b>		
Have you been told you can withdraw from the study at any time?	45	0.75
During the study, will anyone not working with KEMRI or the nearest clinic know about your health information?	44	0.62
At what point can you leave the study?	45	0.94
What does it mean when you sign the study consent form? <sup>a</sup>	45	0.19
What happens if you decide to stop taking part in the study?	45	0.86
Which of the following describes best why the study is being done?	45	0.51
Which of these activities were you asked to take part in today?	45	0.62
Will you be told your HIV test results during the study? <sup>b</sup>	45	N/A
Other activities might be invited to do?	45	0.6
If you test positive for HIV, will you be offered free treatments?	45	0.66
If you are invited to participate in additional interviews for this study, how will you be compensated for your participation?	45	0.73
Which describes one of the main risks involved in the study?	45	0.67
Which describes the main benefit of taking part in the study? <sup>a</sup>	45	0.26
In your own words, can you tell me what makes you eligible to participate in this study? (open)	45	0.9
How long will you be involved in the study? (open)	45	0.86
What will you be asked to do as a participant in the study after you receive your HIV test results? (open) <sup>a</sup>	45	0.47
<b>Adolescents Only</b>		
If you want to join the study, but your parent/guardian does not agree, can you still join the study?	33	0.64
If your parents wants you to join the study, but you do not want to, are you still allowed to refuse? <sup>a</sup>	33	0.45
<b>Unique to Young Adults</b>		
Have you been told that you can freely decide whether you will take part in this study? <sup>b</sup>	12	N/A
How did you decide to join the study? <sup>b</sup>	12	N/A

\* For complete questions with responses, see appendix.

<sup>a</sup> Post hoc analysis with cross tabulations were used to further explore the low correlation coefficient.

<sup>b</sup> A correlation coefficient could not be obtained for this item. Cross tabulations were used to examine relationships within the data.



307

308 Of the two items that were specific to adolescents, one had a low correlation coefficient, *"If your*  
309 *parents want you to join the study, but you do not want to, are you still allowed to refuse?"* For this  
310 item, 22 (67%) participants gave the same response at test and retest, while 10 answered incorrectly  
311 at test and correctly at retest. Correlations for both items specific to young adults could not be run,  
312 but cross tabulations revealed that all answered the question, *"Have you been told that you can*  
313 *freely decide whether you will take part in this study?"* correctly at both test and retest. For the  
314 question, *"How did you decide to join the study?"* 10 (83%) answered correctly at test, while all 12  
315 answered correctly at retest.

316 Of the 18 items with question wording and/or response options specific to parents, three had low  
317 correlation coefficients. For the item *"How did you decide that you and your child would join this*  
318 *study?"* 18 participants (62%) gave the same response at test and retest while eight (28%) answered  
319 correctly at retest only. Similarly, for the item, *"If your child tests positive for HIV, will he or she be*  
320 *offered free treatment?"* 18 (62%) gave the same response at test and retest and 10 (35%) answered  
321 correctly only at retest. For the item, *"Which describes one of the main risks involved in the study?"*  
322 19 (68%) gave the same answer at both time points, while six (21%) answered correctly only at  
323 retest.

324

325 Among the five items for which correlation coefficients could not be obtained, 26 participants (90%)  
326 answered consistently at test and retest on the question: *"Have you been told that you can freely*  
327 *decide whether you and your child will take part in this study?"* For the item, *"Will you and your child*  
328 *be told the results of his or her HIV test results during the study?"* 28 participants (97%) answered  
329 consistently. For the open-ended item, *"In your own words, can you tell me what makes you and*  
330 *your child eligible to participate in this study?"* 25 participants (92%) answered consistently, and 26  
331 participants (90%) answered consistently on the question: *"How long will your child be involved in*

the study?" For the open-ended item: "What will you and your child be asked to do as participants in the study after he/she receives their test results?" 23 participants (79%) answered consistently at test and retest. Finally, with the negative correlation (-1.0) on the item, "What does it mean when you sign the consent form?" 18 parents were consistent at both time points while 10 went from incorrect at test to correct at retest.

## Discussion

The DICCQ (14) proved to be a useful prototype for adaptation with the Kenyan study. Although the parent study was very different from those for which the DICCQ was developed and included minor adolescents and their parents rather than solely adults, we found the comprehensive domain-linked questions highly useful for adaptation. Given the design of our study, we dropped questions related to clinical trials (blinding and placebo), revised questions related to specific study procedures and populations, and added items specific to assenting adolescents. Examination by bioethicists for face and content validity, as well as piloting with relevant local populations, led to further questionnaire revisions. The exercise also led us to clarify some of the information in the informed consent forms.

Psychometric testing (ceiling/floor) led us to modify the open-ended questions as multiple choice items (see final ICCA versions in Appendices). We recognize that open-ended items are ideally the better tool for testing comprehension, since participants can guess multiple choice answers correctly, thus inflating comprehension levels. Nevertheless, we found that writing down answers in their own words (or even telling staff their answers to write them down) was a difficult and off-putting process, and required staff to parse out whether qualitative answers were partially right or wrong. Finally, test-retest correlations suggested moderate to strong temporal stability for items, despite limitations of small sample size and disparate modes of parental consenting.

Our study contributes to ethical discussions about informed consent in Africa in a number of ways. First, the value of a valid and adaptable tool to test comprehension of informed consent in African contexts should be emphasized and articulated. To improve comprehension, one needs an

instrument that can reliably identify areas of sub-standard understanding. With this in hand, these specific areas can then be targeted for interventions. Simply re-reading the entire consent document with the participant may not be enough; one may need instead to focus on certain areas (some perhaps specific to the particular study), ask the prospective participant questions, and emphasize these areas in a subsequent revisiting of the consent process. Second, the comprehension tool could be feasible for research with human participants conducted in resource-constrained settings. The DICCQ is a free, open-source tool that researchers can adapt to their particular research context, although adaptation comes with some costs. In addition, one could recommend that the tool be used selectively, i.e. in large-scale trials involving significant (greater than minimal) risk -- where the stakes for valid informed consent are higher -- rather than all studies involving human participants. These trials are also more likely than others to have sufficient human and other resources to absorb the costs of adapting and implementing the tool, and its use may be more easily integrated into standard operating procedures. It should be noted that some assessments and interventions can be relatively simple. In a prior study on adolescent perceptions of health services, we assessed the understanding of consent by asking six key questions, and selectively revisiting the consent process depending on the answers (30). This enhanced consent process targeted adolescents who planned to participate in HIV-related studies where parental permission had been waived. Thirdly, the development and use of the tool could have implications for the ethical review of research. If such tools are feasible and effective in raising comprehension scores, research ethics committees may recommend (or require) their use in the consent processes of (at least a subset) of research studies. However, some important challenges regarding the use of comprehension assessment tools in consent remain. As some have noted, if full comprehension were a requirement for valid consent, and valid consent was necessary and sufficient for the ethics of research, all research studies involving human participants would likely be unethical (31). It would be unreasonable -- a form of 'research exceptionalism(32)-- to expect vastly higher levels of consent comprehension in research than in other comparable areas of human life. But how much less than full comprehension is 'good

383 enough' for valid informed consent? When should the results of a comprehension assessment  
384 trigger the need for interventions to improve understanding?

385 It is understandable to want a quantifiable threshold of comprehension below which the consent of  
386 participants is invalidated. The threshold would provide an objective indicator of the need for  
387 interventions to improve understanding and also provide a goal for such interventions, i.e. the  
388 intervention should raise comprehension to or above the accepted threshold. It would clearly be  
389 worrying, for example, if the comprehension tool revealed that only 5% of study participants  
390 understood that they could leave the study at any time, for any reason. If there was an agreed-upon  
391 threshold of (say) 65% for understanding that aspect of informed consent, researchers using the tool  
392 would know the magnitude of the problem and what to aim for.

393 However, questions remain about the attainability of such thresholds. First, such thresholds are  
394 likely to be affected by contextual factors. For example, it seems plausible that the threshold for  
395 understanding study risks should be higher when the risks are higher, and lower when they are  
396 lower. Other contextual factors may include the study population involved, nature of the research  
397 question, or social value of the potential results. If this is the case, the acceptable threshold of  
398 comprehension would be a matter of context-sensitive judgment rather than an objective,  
399 quantifiable measure. However, comprehension assessment tools still have utility even if this is the  
400 case. Results of assessment can help inform 'all things considered' judgments about whether  
401 consent comprehension is adequate, particularly when assessments are fine-grained and focus on  
402 specific key elements that participants should know. The tool allows researchers to stipulate and test  
403 for adequate levels of comprehension (say, 70%) on crucial aspects of research participation,  
404 providing research ethics committees with some confidence that serious attention is being paid to  
405 this issue. Where to set these levels is likely to become clearer as the tool is used over time. In  
406 addition, interventions to improve baseline understanding retain their value even if objective  
407 thresholds of acceptable comprehension currently remain elusive. To use an analogy, tools to assess

408 baseline understanding about HIV are valuable even if it is not entirely clear precisely how much you  
409 need to know to be a well-informed, responsible citizen.

410 Finally, for those concerned about quality of informed consent, it should be noted that informed  
411 consent is only one element among others in a suite of protections that should be offered to  
412 research participants. Even if comprehension seems less than ideal, a study may be morally  
413 acceptable if the research is responsibly designed and conducted in other respects (33). These  
414 considerations notwithstanding, our study results reinforce calls to develop innovative and culturally  
415 responsive ways to present research-related information, beyond the standard method of reading  
416 consent forms(28). The impossibility of perfect comprehension, as well as the elusiveness of  
417 objective thresholds of acceptable comprehension, should not be the enemy of comprehension  
418 assessment or evidence-based efforts to improve consent processes.

419 The study has a number of limitations. Rigorous psychometric testing was beyond the scope of our  
420 study. Sample size for validation was small, particularly given the differences in instrumentation for  
421 our three populations. Further, for test-retest, we conducted the first ICCA immediately prior to the  
422 actual study procedures, and the second after the participants had experienced these procedures,  
423 which likely influenced some of their answers at retest. Some parents were not available to meet  
424 with staff for consenting procedures, leading to differences in the opportunity to hear the consent  
425 form read aloud and to ask questions of staff.

426 The paucity of similar African studies on instruments for informed consent comprehension is not  
427 surprising, given the cost and highly technical nature of psychometric development and testing of a  
428 comprehension instrument. Given the difficulties, we found it exceedingly useful to have a non-  
429 proprietary instrument that invited adaptation in other contexts. We also found the adaptation and  
430 validation process was helpful in further fine-tuning, not only our instrument, but also our informed  
431 consent document, to make sure that we were fully and clearly communicating the information

required for human subject protection. We include the final three documents in the Appendix in hopes that they will be useful to other researchers.

## References

1. Nuffield Council on Bioethics. The ethics of research related to healthcare in developing countries, London, UK. 2002. Available from: <http://www.nuffieldbioethics.org/research-developing-countries>. Accessed date 19 November 2013.
2. World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th World. Helsinki, Finland: Medical Association General Assembly, June 1964, and last amended by the 64th World Medical Association General Assembly in Fortaleza, Brazil: October 2013. Available at: <http://jama.jamanetwork.com/article.aspx?articleid=1760318>. Accessed date 18 November 2013.
3. The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. U.S. Department of Health & Human Services. Washington DC. April 18, 1979. Available from: <http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html>. Accessed date 18 November 2013.
4. Department of Health and Human Services. Code of Federal Regulations. Title 45, Public Welfare. Part 46, Protection of Human Subjects, 2009. Available at: <http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html>. Accessed 14 Dec 2017.
5. Beauchamp TL and Childress JS. Principles of Biomedical Ethics. Oxford: Oxford University Press; 2001.
6. Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855-62.
7. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS medicine. 2007;4(11):e324.
8. Krosin MT, Klitzman R, Levin B, Cheng J, Ranney ML. Problems in comprehension of informed consent in rural and peri-urban Mali, West Africa. Clinical Trials. 2006;3(3):306-13.
9. Kruger M, Ndebele P, Horn L. Research Ethics in Africa: A Resource for Research Ethics Committees 2014.
10. Kass NE, Taylor HA, Ali J, Hallez K, Chaisson L. A pilot study of simple interventions to improve informed consent in clinical research: feasibility, approach, and results. Clin Trials. 2015;12(1):54-66.
11. Afolabi MO, Okebe UJ, McGrath N, Larson JH, Bojang K, Chandramohan D. Informed Consent Comprehension in African research settings: A systematic review. Tropical Medicine and International Health. 2014;19(6):625-42.
12. Tam NT, Huy NT, Thoa le TB, Long NP, Trang NT, Hirayama K, et al. Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93(3):186-98h.
13. Mandava A, Pace C, Campbell B, Emanuel E, Grady C. The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries. Journal of medical ethics. 2012.
14. Afolabi MO, Bojang K, D'Alessandro U, Ota MOC, Imoukhuede EB, Ravinetto MR, et al. Digitised audio questionnaire for assessment of informed consent comprehension in a low literacy African research population: Development and psychometric evaluation. BMJ Open. 2014;4:e004817.doi:10.1136/bmjopen-2014-004817.
15. World Bank Indicators 2012 - Gambia - Outcomes. Available from: <http://www.tradingeconomics.com/gambia/literacy-rate-adult-total-percent-of-people-ages-15-and-above-wb-data.html>. Accessed on 2 February 2013 [Internet].



1  
2  
3 479 16. Buccini L, Iverson D, Caputi P, Jones C. A new measure of informed consent comprehension:  
4 480 Part I - Instrument development. Available from <http://works.bepress.com/diverson/18>. Accessed  
5 481 26 July 2012.  
6 482 17. Buccini LD, Iverson, D, Caputi, P., Jones, C. and Gho, S. Assessing clinical trial informed  
7 483 consent comprehension in non-cognitively-impaired adults: a systematic review of instruments.  
8 484 Research Ethics Review. 2009;5(1):3-8.  
9 485 18. Marsh V, Kamuya D, Mlamba A, Williams T, Molyneux S. Experiences with community  
10 486 engagement and informed consent in a genetic cohort study of severe childhood diseases in Kenya.  
11 487 BMC Med Ethics. 2010;11:13.  
12 488 19. Marshall PA. Ethical challenges in study design and informed consent for health research in  
13 489 resource-poor settings: WHO on behalf of Special Programme for Research and Training in Tropical  
14 490 Diseases; 2007.  
15 491 20. Molyneux CS, Peshu N, Marsh K. Understanding of informed consent in a low-income  
16 492 setting: three case studies from the Kenyan Coast. Social Science and Medicine. 2004;59(12):2547-  
17 493 59.  
18 494 21. Mystakidou K, Panagiotou I, Katsaragakis S, Tsilika E, Parpa E. Ethical and practical challenges  
19 495 in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited  
20 496 countries. Journal of Social Aspects of HIV/AIDS Research Alliance. 2009;6(2):46-57.  
21 497 22. Nishimura A, Carey J, Erwin P, Tilburt J, Murad M, McCormick J. Improving understanding in  
22 498 the research informed consent process: a systematic review of 54 interventions tested in  
23 499 randomized control trials. BMC Medical Ethics. 2013;14(1):28.  
24 500 23. Préziosi M, Yam A, Ndiaye M, Simaga A, Simondon F, Wassilak SGF. Practical Experiences in  
25 501 Obtaining Informed Consent for a Vaccine Trial in Rural Africa. New England Journal of Medicine.  
26 502 1997;336(5):370-3.  
27 503 24. Sand K, Kassa S, Loge JH. The Understanding of Informed Consent Information-Definitions  
28 504 and Measurements in Empirical Studies. AJOB Primary Research. 2010;1(2):4-24.  
29 505 25. CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects,  
30 506 prepared by the Council for International Organizations of Medical Sciences, Geneva, Switzerland:  
31 507 3rd edition, 2002. Available from:  
32 508 [http://www.cioms.ch/publications/guidelines/guidelines\\_nov\\_2002\\_blurb.htm](http://www.cioms.ch/publications/guidelines/guidelines_nov_2002_blurb.htm). Accessed 2 June  
33 509 2013.  
34 510 26. Guidelines for scientists: Gambia Government/Medical Research Council Joint Ethics  
35 511 Committee. Banjul, 2000.  
36 512 27. DeVon HA, Block ME, Moyle-Wright P, Ernst DM, Hayden SJ, Lazzara DJ. A psychometric  
37 513 toolbox for testing validity and reliability. Journal of Nursing Scholarship. 2007;39(2):155-64.  
38 514 28. Rennie S, Groves AK, Hallfors DD, Iritani BJ, Odongo FS, Luseno WK. The Significance of  
39 515 Benefit Perceptions for the Ethics of HIV Research Involving Adolescents in Kenya. Journal of  
40 516 empirical research on human research ethics : JERHRE. 2017;12(4):269-79.  
41 517 29. Kolenikov S, Angeles G. The Use of Discrete Data in PCA: Theory, Simulations, and  
42 518 Applications to Socioeconomic Indices. 2004:1-59. Chapel Hill: Carolina Population Center, University  
43 519 of North Carolina. .  
44 520 30. Luseno WK, Iritani B, Zietz S, Maman S, Mbai, II, Otieno F, et al. Experiences along the HIV  
45 521 care continuum: perspectives of Kenyan adolescents and caregivers. African journal of AIDS research  
46 522 : AJAR. 2017;16(3):241-50.  
47 523 31. Bromwich D, Millum JR. Informed consent to HIV cure research. Journal of medical ethics.  
48 524 2017;43(2):108-13.  
49 525 32. Wilson J, Hunter D. Research exceptionalism. The American journal of bioethics : AJOB.  
50 526 2010;10(8):45-54.  
51 527 33. Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing  
52 528 countries ethical? The benchmarks of ethical research. The Journal of infectious diseases.  
53 529 2004;189(5):930-7.

For peer review only

530

531



Adolescent Ethics Research Study  
Adolescents ICCA Questionnaire

The next set of questions will assess your understanding of agreement to participate in the study, including the purpose of the study, what will be expected of you, the benefits, the possible risks, and the safeguards.		
1..	Have you been told you can withdraw from this study at any time? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
2.	During the study, will anyone not working with KEMRI or the nearest clinic know about your health information? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
3.	Have you been given the name and phone number of the person to contact if you have any questions about the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
4.	Will you receive a t-shirt for taking part in the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
5.	How were participants selected into different groups in this study? (Choose one)	1= Participants were divided into different groups based on their health needs 2= Participants were divided into different groups equally by chance. 3= Participants were free to decide which group they would be placed 4= I don't know 8= Refuse to Answer
6.	At what point can you leave the study? (Choose one)	1= I can leave at any time without giving a reason 2= I can only leave with the permission of village elders 3= I can only leave when the study is over 4= I don't know 8= Refuse to Answer
7.	What does it mean when you sign the study consent form? (Choose one)	1= I would like to take part in similar studies 2= I do not want to take part in this study 3= I am agreeing to take part in this study 4= I don't know 8= Refuse to Answer
8.	If you want to join the study, but your parent/guardian does not agree, can you still join the study? (Choose one)	1= Yes, it is my choice alone 2= No, my parent/guardian must agree 3= Yes, if the researchers say that I can 4= I don't know 8= Refuse to Answer
9.	If your parent wants you to join the study, but you do not want to, are you still allowed to refuse? (Choose one)	1= Yes, it is my choice alone 2= No, the parents' wishes must be honored 3= No, the study is important for society 4= I don't know 8= Refuse to Answer

10.	What will happen if you decide to stop taking part in this study? (Choose one)	1= Nothing bad will happen, it is my choice. 2= This decision will affect my access to medical care in the future. 3= I will be fined and punished. 4= I don't know 8= Refuse to Answer
11.	Which of the following describes best why the study is being done? (Choose one)	1= To test new HIV medicines 2= To understand how to do HIV studies with adolescents 3= To check my blood for different diseases 4= I don't know 8= Refuse to Answer
12.	Which of these activities were you asked to take part in today? (Choose one)	1= Survey and HIV test 2= Urine sample collection 3= Body examination by study doctor or nurse 4= I don't know 8= Refuse to Answer
13.	Which other activities might you be invited to do? (Choose one)	1= Interviews 2= Testing medications 3= Reporting to younger adolescents how to prevent HIV 4= I don't know 8= Refuse to Answer
14.	Will you be told your HIV test results during the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
15.	If you test positive for HIV, will you be offered free treatments? (Choose one)	1= Yes, the research team will provide treatment 2= Yes, I will be referred to a local clinic of my choice for free treatment 3= No, I will not be referred to a local clinic for free treatment 4= I don't know 8= Refuse to Answer
16.	If you are invited to participate in additional interviews for this study, how will you be compensated for your participation? (Choose one)	1= A small amount of money in addition to weekly checkups 2= Free medicine, money, and weekly checkups 3= A small amount of food (oil, maize meal or sugar) 4= Money to cover my time for each study visit 8= Refuse to Answer
17.	Which describes one of the main risks involved in the study? (Choose one)	1= Becoming HIV infected 2= Becoming upset by my HIV test result being positive 3= Side effects of drugs 4= I don't know 8= Refuse to Answer

18.	Which describes the main benefit of taking part in the study? (Choose one)	1= To help other adolescents who will be involved in HIV research 2= Free medical care 3= Help with school fees 4= I don't know 8= Refuse to Answer
19.	Which one of the following best describes what makes you eligible to participate in this study? (Choose one)	1= I have not been tested in the last 6 months, have never tested positive, and am 15-17 years old 2= I want to know/learn my HIV status. 3= I was chosen by the computer 4= I don't know
20.	What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (Choose one)	1= There is no difference 2= At the clinic I would go to learn my status, but in this research I am helping researchers know how to conduct HIV research with adolescents 3= At the clinic you have to pay money to be tested but in this study it is free to be tested 4= I don't know
21.	How long will you be in this study? (Choose one)	1= For the duration of 5 years 2= I will be asked by the researchers to give blood one year from today 3= I will most likely be done with the study after today, but there is a small chance I may be asked to come back for 2 more interviews 4= I don't know
Thank you very much for your participation. We appreciate your help in responding to the questions. Kindly ask the research staff anything you do not understand. Do raise your hand for assistance from the research staff to exit.		

Young Adult ICCA Questionnaire

The next set of questions will assess your understanding of agreement to participate in the study, including the purpose of the study, what will be expected of you, the benefits, the possible risks, and the safeguards.		
1.	Have you been told that you can freely decide whether you will take part in this study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
2.	Have you been told you can withdraw from this study at any time? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
3.	During the study, will anyone not working with KEMRI or the nearest clinic know about your health information? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer

4.	Have you been given the name and phone number of the person to contact if you have any questions about the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
5.	Will you receive a t-shirt for taking part in the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
6.	How were participants selected into different groups in this study? (Choose one)	1= Participants were divided into different groups based on their health needs 2= Participants were divided into different groups equally by chance. 3= Participants were free to decide which group they would be placed 4= I don't know 8= Refuse to Answer
7.	At what point can you leave the study? (Choose one)	1= I can leave at any time without giving a reason 2= I can only leave with the permission of village elders 3= I can only leave when the study is over 4= I don't know 8= Refuse to Answer
8.	What does it mean when you sign the study consent form? (Choose one)	1= I would like to take part in similar studies 2= I do not want to take part in this study 3= I am agreeing to take part in this study 4= I don't know 8= Refuse to Answer
9.	How did you decide to join the study? (Choose one)	1= It was decided by the village leaders. 2= It was decided by me and it was completely voluntary 3= It was decided by the scientists and doctors. 4= It was decided by my parents 8= Refuse to Answer
10.	What will happen if you decide to stop taking part in this study? (Choose one)	1= Nothing bad will happen, it is my choice. 2= This decision will affect my access to medical care in the future. 3= I will be fined and punished. 4= I don't know 8= Refuse to Answer
11.	Which of the following describes best why the study is being done? (Choose one)	1= To test new HIV medicines 2= To understand how to do HIV studies with adolescents 3= To check my blood for different diseases 4= I don't know 8= Refuse to Answer
12.	Which of these activities were you asked to take part in today? (Choose one)	1= Survey and HIV test 2= Urine sample collection 3= Body examination by study doctor or nurse 4= I don't know

		8= Refuse to Answer
13.	Which other activities might you be invited to do? (Choose one)	1= Interviews 2= Testing medications 3= Reporting to younger adolescents how to prevent HIV 4= I don't know 8= Refuse to Answer
14.	Will you be told your HIV test results during the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
15.	If you test positive for HIV, will you be offered free treatments? (Choose one)	1= Yes, the research team will provide treatment 2= Yes, I will be referred to a local clinic of my choice for free treatment 3= No, I will not be referred to a local clinic for free treatment 4= I don't know 8= Refuse to Answer
16.	If you are invited to participate in additional interviews for this study, how will you be compensated for your participation? (Choose one)	1= A small amount of money in addition to weekly checkups 2= Free medicine, money, and weekly checkups 3= A small amount of food (oil, maize meal or sugar) 4= Money to cover my time for each study visit 8= Refuse to Answer
17.	Which describes one of the main risks involved in the study? (Choose one)	1= Becoming HIV infected 2= Becoming upset by my HIV test result being positive 3= Side effects of drugs 4= I don't know 8= Refuse to Answer
18.	Which describes the main benefit of taking part in the study? (Choose one)	1= To help other adolescents who will be involved in HIV research 2= Free medical care 3= Help with school fees 4= I don't know 8= Refuse to Answer
19.	Which one of the following best describes what makes you eligible to participate in this study? (Choose one)	1= I have not been tested in the last 6 months, have never tested positive, and am 15-19 years old 2= I want to know/learn my HIV status. 3= I was chosen by the computer 4= I don't know
20.	What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (Choose one)	1= There is no difference 2= At the clinic I would go to learn my status, but in this research I am helping researchers know how to conduct HIV research with adolescents

		<p>3= At the clinic you have to pay money to be tested but in this study it is free to be tested</p> <p>4= I don't know</p>
21.	How long will you be in this study? (Choose one)	<p>1= For the duration of 5 years</p> <p>2= I will be asked by the researchers to give blood one year from today</p> <p>3= I will most likely be done with the study after today, but there is a small chance I may be asked to come back for 2 more interviews</p> <p>4= I don't know</p>
<p>Thank you very much for your participation. We appreciate your help in responding to the questions. Kindly ask the research staff anything you do not understand. Do raise your hand for assistance from the research staff to exit.</p>		

# BMJ Open

## A validation study of an adapted instrument to assess informed consent comprehension among youth and parents in rural western Kenya

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021613.R1
Article Type:	Research
Date Submitted by the Author:	01-May-2018
Complete List of Authors:	Afolabi, Muhammed; London School of Hygiene and Tropical Medicine, Clinical Research Rennie, Stuart; UNC School of Medicine Charlotte Campus Hallfors, Denise; Pacific Institute for Research and Evaluation (PIRE) Kline, Tracy; RTI International Zeitz, Susannah ; University of North Carolina, Department of Health Behavior; Pacific Institute for Research and Evaluation (PIRE) Odongo, Frederick; Center for Global Health Research, Kenya Medical Research Institute (KEMRI) Amek, Nyaguara ; Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Luseno, Winnie; Pacific Institute for Research and Evaluation (PIRE)
<b>Primary Subject Heading</b>:	Ethics
Secondary Subject Heading:	Ethics
Keywords:	informed consent, understanding, tool, validation, Africa

SCHOLARONE™  
Manuscripts



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A validation study of an adapted instrument to assess informed consent comprehension among youth and parents in rural western Kenya**

Muhammed O. Afolabi<sup>1</sup>, Stuart Rennie<sup>2</sup>, Denise Dion Hallfors<sup>3</sup>, Tracy Kline<sup>4</sup>, Susannah Zeitz<sup>3,5</sup>, Frederick S. Odongo<sup>6</sup>, Nyaguara O. Amek<sup>6</sup>, Winnie K. Luseno<sup>3</sup>

<sup>1</sup>Department of Clinical Research, London School of Hygiene & Tropical Medicine, UK;

<sup>2</sup>Department of Social Medicine, UNC School of Medicine, USA;

<sup>3</sup>Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, North Carolina, USA;

<sup>4</sup>RTI International, Research Triangle Park, North Carolina, USA;

<sup>5</sup>Department of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, USA.

<sup>6</sup>Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya

**Corresponding author:** Dr Muhammed Afolabi, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, United Kingdom. E-mail: [Muhammed.Afolabi@lsthm.ac.uk](mailto:Muhammed.Afolabi@lsthm.ac.uk); [afolabimo@gmail.com](mailto:afolabimo@gmail.com)

**Funding Statement:** The research reported in this publication was sponsored by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH102125 (Winfred [Winnie] K. Luseno, Principal Investigator). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Statement of data sharing:** Exclusive use of the data will be maintained by the Principal Investigator (PI), Dr. W. K. Luseno, until the publication of major outputs. Thereafter, following approvals by the institutional review boards of PIRE and KEMRI, de-identified data will made available to the scientific community through requests made to the PI at [wluseno@pire.org](mailto:wluseno@pire.org)

**Competing Interest:** Authors declared no conflict of interest

**Authors' contributions:** Design of study: WL, DH, and MOA; drafting and reviewing questionnaires: DH, WL, MOA, and SR; acquiring data: WL, FSO, and NOA; analysing data: TK, SZ, DH, WL, and MOA; writing the manuscript: MOA, SR, DH, WL, TK, SZ, and NOA.

**Acknowledgements:** The authors thank all the study participants, including the community and youth advisory board members, and field staff who contributed to this Research. This work was done in collaboration with Kenya Medical Research Institute (KEMRI), Center for Global Health Research, Kisumu.



36

## Abstract

**Objective:** To adapt and validate a questionnaire originally developed in a research setting for assessment of comprehension of consent information in a different cultural and linguistic research setting.

**Design:** The adaptation process involved development and customization of a questionnaire for each of the three study groups, modeled closely on the previously validated questionnaire. The three adapted draft questionnaires were further reviewed by two bioethicists and the developer of the original questionnaire for face and content validity. The revised questionnaire was subsequently programmed into an audio-computerized format, with translations and back-translations in three widely spoken languages by the study participants: Luo, Swahili, and English.

**Setting:** The questionnaire was validated amongst adolescents, their parents, and young adults living in Siaya County, a rural region of western Kenya.

**Participants:** 25-item adapted questionnaires consisting of close-ended, multiple-choice, and open-ended questions were administered to 235 participants consisting of 107 adolescents, 92 parents and 36 young adults. Test-retest was conducted 2-4 weeks after first questionnaire administration amongst 74 adolescents, young adults, and parents.

**Outcome measure:** Primary outcome measures included ceiling/floor analysis to identify questions with extremes in responses and item-level correlation to determine the test-retest relationships. Given the data format, tetrachoric correlations were conducted for dichotomous items and polychoric correlations for ordinal items. The qualitative validation assessment included face and content validity evaluation of the adapted instrument by technical experts.

**Results:** Ceiling/floor analysis showed eight question items for which >80% of one or more groups responded correctly, while for nine questions, including all seven open-ended questions, <20% responded correctly. Majority of the question items had moderate to strong test-retest correlation estimates indicating temporal stability.

**Conclusions:** Our study demonstrates that cross-cultural adaptation and validation of an informed consent comprehension questionnaire is feasible. However, further research is needed to develop a tool which can estimate a quantifiable threshold of comprehension thereby serving as an objective indicator of the need for interventions to improve comprehension.

**Keywords:** informed consent, understanding, tool, validation, Africa

#### Strengths and limitations of this study:

- We conducted a cross-cultural adaptability and validation study of an informed consent comprehension tool developed in two differently diverse linguistic settings
- Item-level test-retest reliability, as well as qualitative methods involving face and content validity, were employed to establish reliability and validity of the adapted tool.
- Relatively small sample size and disparate modes of parental consenting posed a unique challenge in validating a tool across many age-groups.
- Our tool did not focus on developing a quantifiable threshold of comprehension below which the consent of participants is invalidated.

## 72 Introduction

73 Informed consent is a key ethical requirement in clinical research. Universally agreed guidelines  
74 highlight four elements of informed consent which normally must be satisfied before proceeding  
75 with the conduct of scientific research involving human participants. These elements include  
76 decisional competence, disclosure of study information, comprehension and voluntariness (1-4). Of  
77 these elements, comprehension of consent information by a prospective research participant is  
78 critical to the quality of a consent procedure as it determines how the participant is empowered to  
79 use the information to arrive at an informed decision on whether or not to participate in the study  
80 (5). The informed consent process is typically built on the notion that individuals considering  
81 participation have demonstrated satisfactory understanding of the consent information (6).  
82 However, empirical evidence has shown that research participants frequently do not understand  
83 significant aspects of the studies they join, such as the difference between participating in clinical  
84 research and receiving medical care, i.e. 'therapeutic misconception'(7). They also demonstrate poor  
85 understanding of the concepts of randomisation, research risk and benefits and right of withdrawal  
86 (8-10).  
87 Very few studies have assessed research participant comprehension of consent information in  
88 African populations. In a systematic review with meta-analysis of 21 studies conducted across  
89 several African countries, comprehension of key concepts of informed consent was poor, with less  
90 than half of the study participants demonstrating understanding of research concepts such as  
91 randomisation and placebo, and with only 30% being aware of participating in clinical research (11).  
92 Conversely, another systematic review focusing on 103 studies conducted mainly in middle and high-  
93 income countries over a period of 30 years, showed that more than 70% of participants had good  
94 understanding of different domains of informed consent including nature of the study, voluntary  
95 participation, and rights of withdrawal while appreciable proportions of the participants  
96 demonstrated no therapeutic misconceptions and were aware of the study risks and benefits (12).

1  
2  
3 97 This contrast between the ideals of informed consent and the reality of informed consent in practice  
4  
5 98 is especially marked in settings with high illiteracy rates or mistrust of research institutions, or where  
6  
7 99 signatures are rarely employed for transacting business. Over-emphasis on written documents can  
8  
9 100 further aggravate these challenges to effective communication, particularly when participants are  
10  
11 101 asked to understand complex information contained in lengthy informed consent documents written  
12  
13 102 in international languages with unfamiliar terms and concepts (13).  
14  
15 103  
16 104 To ensure participants make meaningful decisions that protect their rights and freedom of choice,  
17  
18 105 researchers in socially and economically disadvantaged communities have been advised to make  
19  
20 106 efforts to help prospective participants attain satisfactory understanding of informed consent (2). To  
21  
22 107 help achieve this, a context-sensitive tool is required to assess participant comprehension of  
23  
24 108 components of consent information delivered during an informed consent discussion. The tool  
25  
26 109 would help to indicate areas of miscomprehension and could further serve as a platform to develop  
27  
28 110 appropriate interventions to improve the identified areas which participants do not understand.  
29  
30 111 The development and psychometric evaluation of a Digitised Informed Consent Comprehension  
31  
32 112 Questionnaire (DICCQ) has been reported elsewhere (14). Briefly, the tool was developed following  
33  
34 113 meticulous identification of domains of informed consent which are poorly understood by research  
35  
36 114 participants in low literacy communities in Africa. Owing to the peculiar challenge of inability to read  
37  
38 115 and comprehend informed consent written in international languages, the questionnaire was  
39  
40 116 developed into an audio computerised tool in the participants' local languages. The tool was  
41  
42 117 administered to assess the understanding of individuals participating in studies taking place in rural  
43  
44 118 and urban settings of The Gambia, a small West African country characterised with an adult literacy  
45  
46 119 rate of less than 50% (15). Although the tool was reported to be a reliable and valid measure of  
47  
48 120 informed consent comprehension (14), we expressed concerns regarding whether the tool would  
49  
50 121 retain its acceptable properties if adapted for use in alternate African settings with diverse cultural  
51  
52 122 and linguistic variations.  
53  
54  
55  
56  
57  
58  
59  
60

Given that empirical assessment of consent comprehension is in its infancy and that instrument development and validation are a lengthy but critical process, we focus on the cultural adaptation and evaluation of the DICCQ amongst a diverse population of adolescents, young adults and parents in a rural setting in western Kenya, East Africa. The initial validation of the DICCQ has been previously published (14), and is the basis for the instrument which was modified for relevance and tested among the three age-groups in Kenya. This work is part of a study on the effects of HIV test disclosure on adolescent behavior and well-being to inform guidelines for the ethical conduct of adolescent HIV-related research in sub-Saharan Africa. Along with HIV testing, we are investigating comprehension during the informed consent process among parents and youth. The current paper focuses on the first phase of activities to assess informed consent comprehension. The activities included the adaptation of the DICCQ instrument, which was developed for adults, for use among adolescents and their parents, as well as young adults; content validation, ceiling-floor analysis, and a test-retest assessment of the adapted instrument. Results will be used to determine the final format of the adapted instrument.

### **The original DICCQ: constructs and validation**

As highlighted above, the question items on the DICCQ were generated from basic elements of informed consent obtained from literature on guidelines for contextual development of informed consent tools (13, 16-24), international ethical guidelines (3, 25) and operational guidelines from The Gambia's National Ethics Committee (26). Of these, 15 independent domains of informed consent that were not appropriately understood among study participants in low literacy settings were identified. These domains included voluntary participation, rights of withdrawal, study knowledge, study procedures, study purpose, blinding, confidentiality, compensation, randomization, autonomy, meaning of giving consent, benefits, risks/adverse effects, therapeutic misconception and placebo. DICCQ was face-validated by a carefully selected panel of researchers with expertise in research methodology and bioethics in the African context. The panel assessed the tool's readability, clarity of

words used, consistency of style and likelihood of target participants being able to answer the questions. This same expert panel also assessed content validity to establish whether the content of the questionnaire was appropriate and relevant to the context for which it was developed (27). The tool was revised based on the feedback from these experts. The revised questionnaire was further content-validated by randomly selected research assistants and three independent lay persons to assess clarity and appropriateness of the revised question items and their response options.

Given the lack of acceptable systems of writing in Gambian local languages, the question items were audio-recorded in three major local languages by experienced native speaking linguistic professionals who were also familiar with clinical research concepts. Audio back-translations were done for each language by three independent native speakers and corrections were made in areas where translated versions were not consistent with the English version. A final proof of the audio-recordings was conducted by three native speaking clinical researchers who independently confirmed that the translated versions retained the original meaning of the English version.

The revised questionnaire was developed into an audio computer-assisted self-interview (ACASI) format and referred to as the DICCQ(14). The tool was administered to 250 participants in two studies taking place concurrently in rural and urban Gambian settings. Half of these participants were recalled in one to two weeks after the first administration for a re-test. Previously published findings showed that the DICCQ had good psychometric properties with potential as a useful tool for measuring comprehension of informed consent amongst research participants in low literacy African settings (14).

For the present study, we adapted the DICCQ for three groups: minor adolescents (15-17 years), their parents, and young adults (18-19 years). Although some questions could be considered generic for research studies (such as voluntary participation, confidentiality, and rights of withdrawal), others are specific and required adaptation (such as purpose of the study, benefits, and risks). For minor adolescents and their parents, questions related to voluntary participation also required

173 adaptation for comprehension of concepts related to adolescent assent and parental permission. In  
174 this paper, we describe our validation methods and results, provide the resulting surveys, and  
175 discuss issues related to the assessment of comprehension of study information by participants in  
176 rural sub-Saharan settings. We refer to the adapted questionnaire as the Informed Consent  
177 Comprehension Assessment (ICCA).

## 178 **Methods**

### 179 *Validation Sample*

180 At the start of the parent study, we invited all consented participants from 10 randomly selected  
181 village clusters in one sub-county within Siaya County to respond to the ICCA. The first 235 to agree  
182 comprised the ICCA validation sample. Sample size for validation studies is usually determined with  
183 the aim of minimising standard error of the correlation coefficient for reliability test. Also, 4-10  
184 subjects per question items are recommended to obtain a sufficient sample size in order to ensure  
185 stability of variance-covariance matrix in factor analysis(28, 29). We used these recommendations to  
186 determine our sample size.

187 The validation sample included minor adolescents (n=107), their parents (n=92), and young adults  
188 (n=36). Parents were invited if their adolescent child (or children) was selected for the ICCA study.  
189 More than half of the parents (N=49) who took the ICCA were not consented by staff but rather  
190 signed a consent form that their adolescent brought home to them. *Adaptation and Validation*

### 191 *Procedures*

192 We began our adaptation process by developing an ICCA questionnaire for each of the three groups,  
193 modeled closely on the DICCQ. We then customized two questions for minor adolescents about  
194 voluntary participation (i.e. need for parental permission for participation, and adolescent's rights to  
195 refuse). For parents, questions were adapted as needed to refer to their child as the main study  
196 participant. Finally, questions with study-specific content were developed, using content from IRB-



197 approved consent forms. The three draft adapted questionnaires were then reviewed by two  
198 bioethicists and the developer of the original DICCQ for face and content validity, based on study  
199 protocols and the US federal regulations (4). Suggestions to clarify language and responses from this  
200 expert review were incorporated into the second draft.

201 The revised questionnaire was then programmed for ACASI format, with translations and back-  
202 translations in three languages (Luo, Swahili, and English). Next, we conducted pilot tests of the  
203 questionnaires with local Kenyan parent and youth advisory group members (30) to determine  
204 whether consent form information and ICCA items were consistent/non-contradictory. After each of  
205 the three groups (minor adolescents, young adults, and parents) completed the appropriate version  
206 of the ICCA, we asked participants, individually and in separate focus groups, for their opinions  
207 about the consent form, ICCA questions, administration of the ICCA using ACASI format, and staff  
208 assistance (if requested) to type in responses to the open-ended questions. Based on feedback from  
209 participants, we revised the wording of one question's response categories, dropped one question,  
210 and revised the consent form to more clearly describe all aspects covered in the ICCA.

211 Subsequently, we administered the ICCA to our validation sample 2-4 weeks after consent and  
212 immediately prior to the baseline data collection. Adolescents who consented with the parent-child  
213 form took the Adolescent ICCA; those who consented with the young adult form took the Young  
214 Adult ICCA; and parents took the Parent ICCA. Following recommended guidelines in validation  
215 studies(28, 29), a sub-set of the sample, N=74, were re-tested 1-2 weeks later for test-retest  
216 analyses. To make the procedure objective, participant selection for the re-test was sequential  
217 (every second person), stratified by study site. If one refused, staff continued with the sequence (i.e.,  
218 skipping the next eligible and selecting the following).

#### 219 *Instrumentation*

220 Each ICCA survey consisted of a set of 25 yes/no, multiple-choice, and open-ended questions.  
221 Responses to the yes/no and multiple-choice questions were coded 0-1 for incorrect/correct



answers, respectively. Responses to the open-ended questions were independently coded from completely incorrect to completely correct (0-4) by a panel of three researchers who discussed their scores and, if different, came to consensus on a single score per case. Responses were also dichotomized (0-1=incorrect; 2-4=correct) for ceiling/floor analysis. The three survey tools (Adolescent, Young Adult, and Parent) were generally similar. However, only seven questions and response options were identical across the three samples. Sixteen additional items were identical for adolescents and young adults. Two items were adolescent-specific, two were young adult-specific, and 18 items were parent-specific. In addition to the questions on comprehension of informed consent, the ICCA also included socio-demographic items.

### *Ethical considerations*

Ethical approval was obtained from the Institutional Review Boards of the Pacific Institute for Research and Evaluation (PIRE), USA (IRBNet ID: 601736, Project Code: 0744), and Kenya Medical Research Institute (KEMRI; SSC Protocol No. 2982). Written informed parent/guardian consent and youth assent was obtained for adolescents younger than 18 years old; individuals who were 18 years or older or emancipated minors provided written informed consent. Participation was voluntary and private.

### *Patient and Public Involvement*

To ensure the development of the research questions and outcome measures informed the study participants' priorities, experience, and preferences, the adapted questionnaires were translated into the preferred local languages of the study participants. Given the technical complexity involved in designing the study, the study participants were not directly involved in this stage. Nevertheless, parent, professional, and adolescent advisory committees reviewed all study plans and provided comments. Also, feedback obtained from pilot participants residing in the study area was used to refine the ICCA instruments. We had a team of dedicated staff who were responsible for the recruitment and conduct of the study; the participants were not involved in these processes. There

are no plans to organize a feedback forum where the findings reported in this paper will be disseminated to the study participants and other stakeholders. However, findings from the larger parent study will be disseminated to key stakeholders in the study region, including members of our adult community advisory board and youth advisory board. *Validation and Reliability Data Analysis*

All analyses were conducted using Stata 13.0 (College Station, USA). First, we conducted descriptive statistics to determine the magnitude of missing data in each of the ICCA items as well as questions with extremes in responding, i.e., to which > 80% in any one group responded correctly or incorrectly (ceiling/floor analyses). Because high comprehension is desirable for ethical consent, we were particularly interested in questions which fewer than 20% of the sample answered correctly, since this may indicate a problem in wording, format, or translation, as well as comprehension.

Second, we conducted test-retest analysis to assess temporal stability of the ICCA questions, i.e., whether they were reliable in eliciting the same response at initial presentation (test) and at the second presentation one to two weeks later (re-test). Item level correlations were examined to determine the test-retest relationships. Due to data format, tetrachoric correlations were conducted for dichotomous items and polychoric correlations were conducted for ordinal items (open-ended scores) with the user-created polychoric package (31). We used the following benchmarks to interpret the correlation coefficients: below 0.5 was considered low, 0.5 to 0.69 was moderate, and 0.7 and higher was strong. We interpreted moderate and strong correlation coefficients as indicating acceptable temporal stability. Post-hoc analyses, specifically cross-tabulations of participant responses at test and re-test, were conducted to further explore low correlations and to examine relationships in the data where correlation coefficients could not be obtained.

270

## 271 Results

Table 1 shows the demographics of the validation sample, including age, gender, religion and the relationship between the adolescent and the person who gave permission for the adolescent to join the study. As can be seen, about 71% of adults who gave permission for adolescent study participation identified as parents. **Table 1: Demographic characteristics of study participants, Kenya, 2017**

Demographics	Adolescents	Young Adults	Parents
<b>Age</b>			
Median	16	18	42
Range	15-17	18-19	23-95
Interquartile Range	1	1	19
<b>Gender</b>			
Male	60 (56.1%)	18 (50%)	22 (23.9%)
Female	47 (43.9%)	18 (50%)	70 (76.1%)
<b>Currently enrolled in school: N(%)</b>	105 (98.1%)	26 (72.2%)	N/A
<b>Highest level of education: N(%)</b>			
Never gone to school	0 (0%)	0 (0%)	6 (6.5%)
Did not complete primary (< Std/Class 8)	72 (67.3%)	5 (13.9%)	37 (40.2%)
Completed primary (Std/Class 8)	10 (9.3%)	7 (19.4%)	24 (26.1%)
Did not complete secondary (< Form 4)	25 (23.4%)	24 (66.7%)	10 (10.9%)
Completed secondary (Form 4)	0 (0%)	0 (0%)	12 (13.0%)
College or University	0 (0%)	0 (0%)	3 (3.3%)
<b>Attended vocational school: N(%)</b>	0 (0%)	2 (5.6%)	12 (13.0%)
<b>Religion: N(%)</b>			
Roman Catholic	16 (15.0%)	4 (11.1%)	16 (17.4%)
Protestant/Other Christian	90 (84.1%)	31 (86.1%)	76 (82.6%)
Muslim	0 (0%)	1 (2.8%)	0 (0%)
No Religion	1 (0.9%)	0 (0%)	0 (0%)
<b>Attending religious services once/week or more: N(%)</b>	39 (36.4%)	20 (55.6%)	52 (56.5%)
<b>Relationship with adolescent: N(%)</b>			
Parent	N/A	N/A	65 (70.7%)
Other	N/A	N/A	27 (29.3%)
<b>Staff present at consenting: N(%)</b>	N/A	N/A	43 (46.7%)

Descriptive analyses showed that there were no questions with more than 5% missing data. The item with the largest percentage amount of missing responses (4%) was the open-ended study risk question (*Are there any bad things that could happen by taking part in this study? If yes, what are they?*). Ceiling/floor analysis showed eight questions for which >80% of one or more groups responded correctly, while for nine questions, <20% responded correctly (Table 2). All seven open-ended questions were among the latter category. **Table 2. Ceiling Floor Results by Group, showing percent in each group that got item correct~**

Items that more than 80% of group got right (Ceiling)	Adolescents (age 15-17 years; N=107)	Young Adults (age 18-19 years; N=36)	Parents (N=92)
---	--------------------------------------	--------------------------------------	----------------

T-shirt for Participation	93.5	97.2	80.4*
Study Activities for Youth	91.6	91.7	N/A
HIV Test Results Disclosure	94.4	94.4	90.2
Voluntary Withdrawal	N/A	94.4	85.9
Decisions for Study Participation	N/A	88.9	N/A
What Happens if you stop Study Participation	N/A	86.1	N/A
Purpose of conducting study	N/A	88.9	N/A
Voluntary Participation	N/A	100	93.5

Items that more than 80% of group got wrong (Floor)	Adolescents (age 15-17 years; N=107)	Young Adults (age 18-19 years; N=36)	Parents (N=92)
Mode of Group Selection	19.8	N/A	17.4*
Study Benefits	16.8	16.7	19.6*
Research Purpose (open)**	1.1	13.3	1.1
Study Duration (open)	13.1	N/A	9.8
What is Next after HIV Test Results (open)	14.0	N/A	N/A
Study HIV Test Vs Clinic HCT (open)	7.7	0	2.2
Study Risks (open)	9.3	N/A	13.0
Whom to Call (open)	10.5	19.4	19.6*
Study Eligibility (open)	N/A	N/A	7.7

~ Percent only shown if ceiling/floor cutoff met.

\* Parents who consented without staff present would not have met criterion for ceiling; parents who consented with staff would not meet criterion for floor.

\*\* (open) denotes open-ended questions, (response range = 0-4). These were dichotomized for floor/ceiling analysis: 0=0-1, 1=2-4.

N/A Less than 80 percent of the sample (by population) got these items correct (upper panel) or incorrect (lower panel).

As shown in Table 3, the great majority of items, when analyzed within groupings of the same wording, had moderate to strong test-retest correlation estimates, despite small sample size, suggesting temporal stability. These included all seven items with identical question and response wording for the entire test-retest sample (n=74); 12 of the 16 items with identical question wording and response options for young adults and adolescents (n=45); one of the two questions specific to adolescents (n=33); and 10 of the 18 questions specific to parents (n=29). Seven items, however, had

low correlations, while eight could not be estimated because of small sample sizes and/or near perfect correlation.

Three of the 16 items with identical question/response wording for young adults and adolescents had low correlation coefficients ranging between 0.19 and 0.47. Of these, one was the open-ended item, *"What will you be asked to do as a participant in the study after you receive your HIV test results?"* In cross tabulation, 34 participants (77%) gave the same response at test and retest while, six answered correctly at test and incorrectly at retest. For the item, *"What does it mean when you sign the study consent form?"* 26 (58%) gave the same answer at test and retest, while three answered correctly at test and incorrectly at retest. For the item, *"Which describes the main benefit of taking part in the study?"* 34 participants (75%) gave the same answer at both test and retest, while seven answered incorrectly at test and correctly at retest. Finally, a correlation coefficient could not be obtained for the item *"Will you be told your HIV test results during the study?"* because of a lack of variation at retest, with 41 (91%) and 45 (100%) answering correctly at test and retest, respectively.

**Table 3. Correlational Results for Questions Common to All and Specific to Adolescents, Young Adults, and Parents (n=74)\***

Question	N	Tetrachoric/ Polychoric
<b>Common to All</b>		
Have you been given the name and phone number of the person to contact if you have any questions about the study?	74	0.86
Will you receive a T-shirt for taking part in the study?	74	0.6
How were participants selected into different groups in this study?	74	0.57
In your own words, can you tell me what the purpose of the research study is? (open)	73	-0.92
What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (open)	72	0.87
Are there any bad things that could happen by taking part in this study? If yes, what are they? (open)	70	0.9
If you had a question or concern about the study, who would you call? (open)	74	0.72
<b>Young Adults and Adolescents</b>		
Have you been told you can withdraw from the study at any time?	45	0.75
During the study, will anyone not working with KEMRI or the nearest clinic know about your health information?	44	0.62
At what point can you leave the study?	45	0.94
What does it mean when you sign the study consent form? <sup>a</sup>	45	0.19
What happens if you decide to stop taking part in the study?	45	0.86
Which of the following describes best why the study is being done?	45	0.51
Which of these activities were you asked to take part in today?	45	0.62
Will you be told your HIV test results during the study? <sup>b</sup>	45	N/A
Other activities might be invited to do?	45	0.6
If you test positive for HIV, will you be offered free treatments?	45	0.66
If you are invited to participate in additional interviews for this study, how will you be compensated for your participation?	45	0.73
Which describes one of the main risks involved in the study?	45	0.67
Which describes the main benefit of taking part in the study? <sup>a</sup>	45	0.26
In your own words, can you tell me what makes you eligible to participate in this study? (open)	45	0.9
How long will you be involved in the study? (open)	45	0.86
What will you be asked to do as a participant in the study after you receive your HIV test results? (open) <sup>a</sup>	45	0.47
<b>Adolescents Only</b>		
If you want to join the study, but your parent/guardian does not agree, can you still join the study?	33	0.64
If your parents wants you to join the study, but you do not want to, are you still allowed to refuse? <sup>a</sup>	33	0.45
<b>Unique to Young Adults</b>		

Have you been told that you can freely decide whether you will take part in this study? <sup>b</sup>	12	N/A
How did you decide to join the study? <sup>b</sup>	12	N/A

\* For complete questions with responses, see appendix.

<sup>a</sup> Post hoc analysis with cross tabulations were used to further explore the low correlation coefficient.

<sup>b</sup> A correlation coefficient could not be obtained for this item. Cross tabulations were used to examine relationships within the data.

Of the two items that were specific to adolescents, one had a low correlation coefficient, *"If your parents want you to join the study, but you do not want to, are you still allowed to refuse?"* For this item, 22 (67%) participants gave the same response at test and retest, while 10 answered incorrectly at test and correctly at retest. Correlations for both items specific to young adults could not be run, but cross tabulations revealed that all answered the question, *"Have you been told that you can freely decide whether you will take part in this study?"* correctly at both test and retest. For the question, *"How did you decide to join the study?"* 10 (83%) answered correctly at test, while all 12 answered correctly at retest.

Of the 18 items with question wording and/or response options specific to parents, three had low correlation coefficients. For the item *"How did you decide that you and your child would join this study?"* 18 participants (62%) gave the same response at test and retest while eight (28%) answered correctly at retest only. Similarly, for the item, *"If your child tests positive for HIV, will he or she be offered free treatment?"* 18 (62%) gave the same response at test and retest and 10 (35%) answered correctly only at retest. For the item, *"Which describes one of the main risks involved in the study?"* 19 (68%) gave the same answer at both time points, while six (21%) answered correctly only at retest.

Among the five items for which correlation coefficients could not be obtained, 26 participants (90%) answered consistently at test and retest on the question: *"Have you been told that you can freely decide whether you and your child will take part in this study?"* For the item, *"Will you and your child be told the results of his or her HIV test results during the study?"* 28 participants (97%) answered



consistently. For the open-ended item, *"In your own words, can you tell me what makes you and your child eligible to participate in this study?"* 25 participants (92%) answered consistently, and 26 participants (90%) answered consistently on the question: *"How long will your child be involved in the study?"* For the open-ended item: *"What will you and your child be asked to do as participants in the study after he/she receives their test results?"* 23 participants (79%) answered consistently at test and retest. Finally, with the negative correlation (-1.0) on the item, *"What does it mean when you sign the consent form?"* 18 parents were consistent at both time points while 10 went from incorrect at test to correct at retest.

## Discussion

The DICCQ (14) proved to be a useful prototype for adaptation with the Kenyan study. Although the parent study was very different from those for which the DICCQ was developed and included minor adolescents and their parents rather than solely adults, we found the comprehensive domain-linked questions highly useful for adaptation. Given the design of our study, we dropped questions related to clinical trials (blinding and placebo), revised questions related to specific study procedures and populations, and added items specific to assenting adolescents. Examination by bioethicists for face and content validity, as well as piloting with relevant local populations, led to further questionnaire revisions. The exercise also led us to clarify some of the information in the informed consent forms. Psychometric testing (ceiling/floor) led us to modify the open-ended questions as multiple choice items (see final ICCA versions in Appendices). We recognize that open-ended items are ideally the better tool for testing comprehension, since participants can guess multiple choice answers correctly, thus inflating comprehension levels. Nevertheless, we found that writing down answers in their own words (or even telling staff their answers to write them down) was a difficult and off-putting process, and required staff to parse out whether qualitative answers were partially right or wrong. Finally, test-retest correlations suggested moderate to strong temporal stability for items, despite limitations of small sample size and disparate modes of parental consenting.

Our study contributes to ethical discussions about informed consent in Africa in a number of ways. First, the value of a valid and adaptable tool to test comprehension of informed consent in African contexts should be emphasized and articulated. To improve comprehension, one needs an instrument that can reliably identify areas of sub-standard understanding. With this in hand, these specific areas can then be targeted for interventions. Simply re-reading the entire consent document with the participant may not be enough; one may need instead to focus on certain areas (some perhaps specific to the particular study), ask the prospective participant questions, and emphasize these areas in a subsequent revisiting of the consent process. Second, the comprehension tool could be feasible for research with human participants conducted in resource-constrained settings. The DICCQ is a free, open-source tool that researchers can adapt to their particular research context, although adaptation comes with some costs. In addition, one could recommend that the tool be used selectively, i.e. in large-scale trials involving significant (greater than minimal) risk -- where the stakes for valid informed consent are higher -- rather than all studies involving human participants. These trials are also more likely than others to have sufficient human and other resources to absorb the costs of adapting and implementing the tool, and its use may be more easily integrated into standard operating procedures. It should be noted that some assessments and interventions can be relatively simple. In a prior study on adolescent perceptions of health services, we assessed the understanding of consent by asking six key questions, and selectively revisiting the consent process depending on the answers (32). This enhanced consent process targeted adolescents who planned to participate in HIV-related studies where parental permission had been waived. Thirdly, the development and use of the tool could have implications for the ethical review of research. If such tools are feasible and effective in raising comprehension scores, research ethics committees may recommend (or require) their use in the consent processes of (at least a subset) of research studies. However, some important challenges regarding the use of comprehension assessment tools in consent remain. As some have noted, if full comprehension were a requirement for valid consent, and valid consent was necessary and sufficient for the ethics of research, all research studies

413 involving human participants would likely be unethical (33). It would be unreasonable -- a form of  
414 'research exceptionalism(34)-- to expect vastly higher levels of consent comprehension in research  
415 than in other comparable areas of human life. But how much less than full comprehension is 'good  
416 enough' for valid informed consent? When should the results of a comprehension assessment  
417 trigger the need for interventions to improve understanding?

418 It is understandable to want a quantifiable threshold of comprehension below which the consent of  
419 participants is invalidated. The threshold would provide an objective indicator of the need for  
420 interventions to improve understanding and also provide a goal for such interventions, i.e. the  
421 intervention should raise comprehension to or above the accepted threshold. It would clearly be  
422 worrying, for example, if the comprehension tool revealed that only 5% of study participants  
423 understood that they could leave the study at any time, for any reason. If there was an agreed-upon  
424 threshold of (say) 65% for understanding that aspect of informed consent, researchers using the tool  
425 would know the magnitude of the problem and what to aim for.

426 However, questions remain about the attainability of such thresholds. First, such thresholds are  
427 likely to be affected by contextual factors. For example, it seems plausible that the threshold for  
428 understanding study risks should be higher when the risks are higher, and lower when they are  
429 lower. Other contextual factors may include the study population involved, nature of the research  
430 question, or social value of the potential results. If this is the case, the acceptable threshold of  
431 comprehension would be a matter of context-sensitive judgment rather than an objective,  
432 quantifiable measure. However, comprehension assessment tools still have utility even if this is the  
433 case. Results of assessment can help inform 'all things considered' judgments about whether  
434 consent comprehension is adequate, particularly when assessments are fine-grained and focus on  
435 specific key elements that participants should know. The tool allows researchers to stipulate and test  
436 for adequate levels of comprehension (say, 70%) on crucial aspects of research participation,  
437 providing research ethics committees with some confidence that serious attention is being paid to

438 this issue. Where to set these levels is likely to become clearer as the tool is used over time. In  
439 addition, interventions to improve baseline understanding retain their value even if objective  
440 thresholds of acceptable comprehension currently remain elusive. To use an analogy, tools to assess  
441 baseline understanding about HIV are valuable even if it is not entirely clear precisely how much you  
442 need to know to be a well-informed, responsible citizen.

443 Finally, for those concerned about quality of informed consent, it should be noted that informed  
444 consent is only one element among others in a suite of protections that should be offered to  
445 research participants. Even if comprehension seems less than ideal, a study may be morally  
446 acceptable if the research is responsibly designed and conducted in other respects (35). These  
447 considerations notwithstanding, our study results reinforce calls to develop innovative and culturally  
448 responsive ways to present research-related information, beyond the standard method of reading  
449 consent forms(30). The impossibility of perfect comprehension, as well as the elusiveness of  
450 objective thresholds of acceptable comprehension, should not be the enemy of comprehension  
451 assessment or evidence-based efforts to improve consent processes.

452 The study has a number of limitations. Rigorous psychometric testing was beyond the scope of our  
453 study and therefore face validation and expert evaluation were used. Sample size for validation was  
454 small, particularly given the differences in instrumentation for our three populations. Ceiling and  
455 floor effects, while extensively limiting the item operational range, provided insight into item  
456 functioning and informed modifications needed for the ICCA response options, and the current data  
457 was recoded to reflect those needs. Further, for test-retest, we conducted the first ICCA immediately  
458 prior to the actual study procedures, and the second after the participants had experienced these  
459 procedures, which likely influenced some of their answers at retest. Some parents were not  
460 available to meet with staff for consenting procedures, leading to differences in the opportunity to  
461 hear the consent form read aloud and to ask questions of staff.

1  
2  
3 462 The paucity of similar African studies on instruments for informed consent comprehension is not  
4  
5 463 surprising, given the cost and highly technical nature of psychometric development and testing of a  
6  
7 464 comprehension instrument. Given the difficulties, we found it exceedingly useful to have a non-  
8  
9 465 proprietary instrument that invited adaptation in other contexts. We also found the adaptation and  
10  
11 466 validation process was helpful in further fine-tuning, not only our instrument, but also our informed  
12  
13 467 consent document, to make sure that we were fully and clearly communicating the information  
14  
15 468 required for human subject protection. We include the final three documents in the Appendix in  
16  
17 469 hopes that they will be useful to other researchers.

20  
21 470 **References**

22 471 1. Nuffield Council on Bioethics. The ethics of research related to healthcare in developing  
23 472 countries, London, UK. 2002. Available from: [http://www.nuffieldbioethics.org/research-developing-](http://www.nuffieldbioethics.org/research-developing-countries)  
24 473 [countries](http://www.nuffieldbioethics.org/research-developing-countries). Accessed date 19 November 2013.

25 474 2. World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research  
26 475 Involving Human Subjects Adopted by the 18th World. Helsinki, Finland: Medical Association General  
27 476 Assembly, June 1964, and last amended by the 64th World Medical Association General Assembly in  
28 477 Fortaleza, Brazil: October 2013. Available at:  
29 478 <http://jama.jamanetwork.com/article.aspx?articleid=1760318>. Accessed date 18 November 2013.

30 479 3. The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects  
31 480 of Research. U.S. Department of Health & Human Services. Washington DC. April 18, 1979. Available  
32 481 from: <http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html>. Accessed date 18  
33 482 November 2013.

34 483 4. Department of Health and Human Services. Code of Federal Regulations. Title 45, Public  
35 484 Welfare. Part 46, Protection of Human Subjects, 2009. Available at:  
36 485 <http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html>. Accessed 14 Dec 2017.

37 486 5. Beauchamp TL and Childress JS. Principles of Biomedical Ethics. Oxford: Oxford University  
38 487 Press; 2001.

39 488 6. Grady C. Enduring and emerging challenges of informed consent. N Engl J Med.  
40 489 2015;372(9):855-62.

41 490 7. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. Clinical trials and  
42 491 medical care: defining the therapeutic misconception. PLoS medicine. 2007;4(11):e324.

43 492 8. Krosin MT, Klitzman R, Levin B, Cheng J, Ranney ML. Problems in comprehension of informed  
44 493 consent in rural and peri-urban Mali, West Africa. Clinical Trials. 2006;3(3):306-13.

45 494 9. Kruger M, Ndebele P, Horn L. Research Ethics in Africa: A Resource for Research Ethics  
46 495 Committees2014.

47 496 10. Kass NE, Taylor HA, Ali J, Hallez K, Chaisson L. A pilot study of simple interventions to  
48 497 improve informed consent in clinical research: feasibility, approach, and results. Clin Trials.  
49 498 2015;12(1):54-66.

50 499 11. Afolabi MO, Okebe UJ, McGrath N, Larson JH, Bojang K, Chandramohan D. Informed Consent  
51 500 Comprehension in African research settings: A systematic review. Tropical Medicine and  
52 501 International Health. 2014;19(6):625-42.

12. Tam NT, Huy NT, Thoa le TB, Long NP, Trang NT, Hirayama K, et al. Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. *Bull World Health Organ.* 2015;93(3):186-98h.
13. Mandava A, Pace C, Campbell B, Emanuel E, Grady C. The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries. *Journal of medical ethics.* 2012.
14. Afolabi MO, Bojang K, D'Alessandro U, Ota MOC, Imoukhuede EB, Ravinetto MR, et al. Digitised audio questionnaire for assessment of informed consent comprehension in a low literacy African research population: Development and psychometric evaluation. *BMJ Open.* 2014;4:e004817.doi:10.1136/bmjopen-2014-004817.
15. World Bank Indicators 2012 - Gambia - Outcomes. Available from: <http://www.tradingeconomics.com/gambia/literacy-rate-adult-total-percent-of-people-ages-15-and-above-wb-data.html>. Accessed on 2 February 2013 [Internet].
16. Buccini L, Iverson D, Caputi P, Jones C. A new measure of informed consent comprehension: Part I - Instrument development. Available from <http://works.bepress.com/diverson/18>. Accessed 26 July 2012.
17. Buccini LD, Iverson, D, Caputi, P., Jones, C. and Gho, S. Assessing clinical trial informed consent comprehension in non-cognitively-impaired adults: a systematic review of instruments. *Research Ethics Review.* 2009;5(1):3-8.
18. Marsh V, Kamuya D, Mlamba A, Williams T, Molyneux S. Experiences with community engagement and informed consent in a genetic cohort study of severe childhood diseases in Kenya. *BMC Med Ethics.* 2010;11:13.
19. Marshall PA. Ethical challenges in study design and informed consent for health research in resource-poor settings: WHO on behalf of Special Programme for Research and Training in Tropical Diseases; 2007.
20. Molyneux CS, Peshu N, Marsh K. Understanding of informed consent in a low-income setting: three case studies from the Kenyan Coast. *Social Science and Medicine.* 2004;59(12):2547-59.
21. Mystakidou K, Panagiotou I, Katsaragakis S, Tsilika E, Parpa E. Ethical and practical challenges in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited countries. *Journal of Social Aspects of HIV/AIDS Research Alliance.* 2009;6(2):46-57.
22. Nishimura A, Carey J, Erwin P, Tilburt J, Murad M, McCormick J. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. *BMC Medical Ethics.* 2013;14(1):28.
23. Préziosi M, Yam A, Ndiaye M, Simaga A, Simondon F, Wassilak SGF. Practical Experiences in Obtaining Informed Consent for a Vaccine Trial in Rural Africa. *New England Journal of Medicine.* 1997;336(5):370-3.
24. Sand K, Kassa S, Loge JH. The Understanding of Informed Consent Information-Definitions and Measurements in Empirical Studies. *AJOB Primary Research.* 2010;1(2):4-24.
25. CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects, prepared by the Council for International Organizations of Medical Sciences, Geneva, Switzerland: 3rd edition, 2002. Available from: [http://www.cioms.ch/publications/guidelines/guidelines\\_nov\\_2002\\_blurb.htm](http://www.cioms.ch/publications/guidelines/guidelines_nov_2002_blurb.htm). Accessed 2 June 2013.
26. Guidelines for scientists: Gambia Government/Medical Research Council Joint Ethics Committee. Banjul, 2000.
27. DeVon HA, Block ME, Moyle-Wright P, Ernst DM, Hayden SJ, Lazzara DJ. A psychometric toolbox for testing validity and reliability. *Journal of Nursing Scholarship.* 2007;39(2):155-64.
28. Kline P. *Handbook of Psychological Testing.* 2nd, editor. London: Routledge; 2000.
29. Nunnally JC, Bernstein IH. *Psychometric theory.* 3rd ed. ed. New York, NY: McGraw-Hill; 1994.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

30. Rennie S, Groves AK, Hallfors DD, Iritani BJ, Odongo FS, Luseno WK. The Significance of Benefit Perceptions for the Ethics of HIV Research Involving Adolescents in Kenya. *Journal of empirical research on human research ethics : JERHRE*. 2017;12(4):269-79.

31. Kolenikov S, Angeles G. The Use of Discrete Data in PCA: Theory, Simulations, and Applications to Socioeconomic Indices. 2004:1-59. Chapel Hill: Carolina Population Center, University of North Carolina. .

32. Luseno WK, Iritani B, Zietz S, Maman S, Mbai, II, Otieno F, et al. Experiences along the HIV care continuum: perspectives of Kenyan adolescents and caregivers. *African journal of AIDS research : AJAR*. 2017;16(3):241-50.

33. Bromwich D, Millum JR. Informed consent to HIV cure research. *Journal of medical ethics*. 2017;43(2):108-13.

34. Wilson J, Hunter D. Research exceptionalism. *The American journal of bioethics : AJOB*. 2010;10(8):45-54.

35. Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. *The Journal of infectious diseases*. 2004;189(5):930-7.



## Adolescent Ethics Research Study

### Adolescents ICCA Questionnaire

The next set of questions will assess your understanding of agreement to participate in the study, including the purpose of the study, what will be expected of you, the benefits, the possible risks, and the safeguards.		
1..	Have you been told you can withdraw from this study at any time? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
2.	During the study, will anyone not working with KEMRI or the nearest clinic know about your health information? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
3.	Have you been given the name and phone number of the person to contact if you have any questions about the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
4.	Will you receive a t-shirt for taking part in the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
5.	How were participants selected into different groups in this study? (Choose one)	1= Participants were divided into different groups based on their health needs 2= Participants were divided into different groups equally by chance. 3= Participants were free to decide which group they would be placed 4= I don't know 8= Refuse to Answer
6.	At what point can you leave the study? (Choose one)	1= I can leave at any time without giving a reason 2= I can only leave with the permission of village elders 3= I can only leave when the study is over 4= I don't know 8= Refuse to Answer
7.	What does it mean when you sign the study consent form? (Choose one)	1= I would like to take part in similar studies 2= I do not want to take part in this study 3= I am agreeing to take part in this study 4= I don't know 8= Refuse to Answer
8.	If you want to join the study, but your parent/guardian does not agree, can you still join the study? (Choose one)	1= Yes, it is my choice alone 2= No, my parent/guardian must agree 3= Yes, if the researchers say that I can 4= I don't know 8= Refuse to Answer
9.	If your parent wants you to join the study, but you do not want to, are you still allowed to refuse? (Choose one)	1= Yes, it is my choice alone 2= No, the parents' wishes must be honored 3= No, the study is important for society 4= I don't know 8= Refuse to Answer

10.	What will happen if you decide to stop taking part in this study? (Choose one)	1= Nothing bad will happen, it is my choice. 2= This decision will affect my access to medical care in the future. 3= I will be fined and punished. 4= I don't know 8= Refuse to Answer
11.	Which of the following describes best why the study is being done? (Choose one)	1= To test new HIV medicines 2= To understand how to do HIV studies with adolescents 3= To check my blood for different diseases 4= I don't know 8= Refuse to Answer
12.	Which of these activities were you asked to take part in today? (Choose one)	1= Survey and HIV test 2= Urine sample collection 3= Body examination by study doctor or nurse 4= I don't know 8= Refuse to Answer
13.	Which other activities might you be invited to do? (Choose one)	1= Interviews 2= Testing medications 3= Reporting to younger adolescents how to prevent HIV 4= I don't know 8= Refuse to Answer
14.	Will you be told your HIV test results during the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
15.	If you test positive for HIV, will you be offered free treatments? (Choose one)	1= Yes, the research team will provide treatment 2= Yes, I will be referred to a local clinic of my choice for free treatment 3= No, I will not be referred to a local clinic for free treatment 4= I don't know 8= Refuse to Answer
16.	If you are invited to participate in additional interviews for this study, how will you be compensated for your participation? (Choose one)	1= A small amount of money in addition to weekly checkups 2= Free medicine, money, and weekly checkups 3= A small amount of food (oil, maize meal or sugar) 4= Money to cover my time for each study visit 8= Refuse to Answer
17.	Which describes one of the main risks involved in the study? (Choose one)	1= Becoming HIV infected 2= Becoming upset by my HIV test result being positive 3= Side effects of drugs 4= I don't know 8= Refuse to Answer

18.	Which describes the main benefit of taking part in the study? (Choose one)	1= To help other adolescents who will be involved in HIV research 2= Free medical care 3= Help with school fees 4= I don't know 8= Refuse to Answer
19.	Which one of the following best describes what makes you eligible to participate in this study? (Choose one)	1= I have not been tested in the last 6 months, have never tested positive, and am 15-17 years old 2= I want to know/learn my HIV status. 3= I was chosen by the computer 4= I don't know
20.	What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (Choose one)	1= There is no difference 2= At the clinic I would go to learn my status, but in this research I am helping researchers know how to conduct HIV research with adolescents 3= At the clinic you have to pay money to be tested but in this study it is free to be tested 4= I don't know
21.	How long will you be in this study? (Choose one)	1= For the duration of 5 years 2= I will be asked by the researchers to give blood one year from today 3= I will most likely be done with the study after today, but there is a small chance I may be asked to come back for 2 more interviews 4= I don't know
Thank you very much for your participation. We appreciate your help in responding to the questions. Kindly ask the research staff anything you do not understand. Do raise your hand for assistance from the research staff to exit.		

### Young Adult ICCA Questionnaire

The next set of questions will assess your understanding of agreement to participate in the study, including the purpose of the study, what will be expected of you, the benefits, the possible risks, and the safeguards.		
1.	Have you been told that you can freely decide whether you will take part in this study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
2.	Have you been told you can withdraw from this study at any time? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
3.	During the study, will anyone not working with KEMRI or the nearest clinic know about your health information? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer

4.	Have you been given the name and phone number of the person to contact if you have any questions about the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
5.	Will you receive a t-shirt for taking part in the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
6.	How were participants selected into different groups in this study? (Choose one)	1= Participants were divided into different groups based on their health needs 2= Participants were divided into different groups equally by chance. 3= Participants were free to decide which group they would be placed 4= I don't know 8= Refuse to Answer
7.	At what point can you leave the study? (Choose one)	1= I can leave at any time without giving a reason 2= I can only leave with the permission of village elders 3= I can only leave when the study is over 4= I don't know 8= Refuse to Answer
8.	What does it mean when you sign the study consent form? (Choose one)	1= I would like to take part in similar studies 2= I do not want to take part in this study 3= I am agreeing to take part in this study 4= I don't know 8= Refuse to Answer
9.	How did you decide to join the study? (Choose one)	1= It was decided by the village leaders. 2= It was decided by me and it was completely voluntary 3= It was decided by the scientists and doctors. 4= It was decided by my parents 8= Refuse to Answer
10.	What will happen if you decide to stop taking part in this study? (Choose one)	1= Nothing bad will happen, it is my choice. 2= This decision will affect my access to medical care in the future. 3= I will be fined and punished. 4= I don't know 8= Refuse to Answer
11.	Which of the following describes best why the study is being done? (Choose one)	1= To test new HIV medicines 2= To understand how to do HIV studies with adolescents 3= To check my blood for different diseases 4= I don't know 8= Refuse to Answer
12.	Which of these activities were you asked to take part in today? (Choose one)	1= Survey and HIV test 2= Urine sample collection 3= Body examination by study doctor or nurse 4= I don't know

		8= Refuse to Answer
13.	Which other activities might you be invited to do? (Choose one)	1= Interviews 2= Testing medications 3= Reporting to younger adolescents how to prevent HIV 4= I don't know 8= Refuse to Answer
14.	Will you be told your HIV test results during the study? (Choose one)	1= Yes 2= No 3= I don't know 8= Refuse to answer
15.	If you test positive for HIV, will you be offered free treatments? (Choose one)	1= Yes, the research team will provide treatment 2= Yes, I will be referred to a local clinic of my choice for free treatment 3= No, I will not be referred to a local clinic for free treatment 4= I don't know 8= Refuse to Answer
16.	If you are invited to participate in additional interviews for this study, how will you be compensated for your participation? (Choose one)	1= A small amount of money in addition to weekly checkups 2= Free medicine, money, and weekly checkups 3= A small amount of food (oil, maize meal or sugar) 4= Money to cover my time for each study visit 8= Refuse to Answer
17.	Which describes one of the main risks involved in the study? (Choose one)	1= Becoming HIV infected 2= Becoming upset by my HIV test result being positive 3= Side effects of drugs 4= I don't know 8= Refuse to Answer
18.	Which describes the main benefit of taking part in the study? (Choose one)	1= To help other adolescents who will be involved in HIV research 2= Free medical care 3= Help with school fees 4= I don't know 8= Refuse to Answer
19.	Which one of the following best describes what makes you eligible to participate in this study? (Choose one)	1= I have not been tested in the last 6 months, have never tested positive, and am 15-19 years old 2= I want to know/learn my HIV status. 3= I was chosen by the computer 4= I don't know
20.	What is the difference between taking part in this study and going to the clinic for voluntary HIV testing? (Choose one)	1= There is no difference 2= At the clinic I would go to learn my status, but in this research I am helping researchers know how to conduct HIV research with adolescents

		<p>3= At the clinic you have to pay money to be tested but in this study it is free to be tested</p> <p>4= I don't know</p>
21.	How long will you be in this study? (Choose one)	<p>1= For the duration of 5 years</p> <p>2= I will be asked by the researchers to give blood one year from today</p> <p>3= I will most likely be done with the study after today, but there is a small chance I may be asked to come back for 2 more interviews</p> <p>4= I don't know</p>
<p>Thank you very much for your participation. We appreciate your help in responding to the questions. Kindly ask the research staff anything you do not understand. Do raise your hand for assistance from the research staff to exit.</p>		